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ABSTRACT
The Combined Neuropharmacology and Toxicology of Major ‘Bath Salts’ Constituents
MDPV, Mephedrone, and Methylone
by
Serena Allen
The synthetic cathinones, 3,4- methylenedioxypyrovalerone (MDPV), 4methylmethcathinone (mephedrone), and 3,4- methylenedioxymethcathinone
(methylone), gained worldwide notoriety as the psychoactive components of ‘bath salts;’
a marketing term used to circumvent federal drug laws and permit their legal sale.
Previous studies have shown that these drugs share pharmacological characteristics
with cocaine and the amphetamines, however, descriptions of their neurotoxic
properties are limited. Moreover, while forensic analysis has revealed that the most
frequently abused bath salts ‘brands’ contain binary and ternary mixtures of MDPV,
mephedrone, and methylone, the majority of preclinical research has focused on
explicating the individual effects of these drugs. Therefore, the present dissertation
aimed to address this limitation and characterize the acute and chronic effects of
combined synthetic cathinone exposure on dopaminergic tone in mesolimbic and
nigrostriatal brain regions. To accomplish this, male Swiss-Webster mice were
administered MDPV, mephedrone, and methylone, individually or concomitantly, 1 time
or 7 times over the course of two weeks and the corresponding effects of each
treatment on mesolimbic and nigrostriatal brain tissue levels of dopamine (DA) and DA
metabolites were analyzed using a high performance liquid chromatography –
electrochemical detection (HPLC-ECD) assay. Additionally, motor-stimulant activity
was evaluated after both dosing regimens using locomotor activity assays, while
2

immunoblot and immunostaining techniques were used to evaluate the chronic effects
of co-synthetic cathinone exposure on tissue levels of tyrosine hydroxylase (TH),
dopamine transporter (DAT), monoamine oxidase B (MAO-B), catechol-Omethyltransferase (COMT), and glial fibrillary acidic protein (GFAP). Results from these
studies provide evidence of a significant pharmacological interaction among major bath
salt constituents, MDPV, mephedrone, and methylone. This was observed acutely as
enhanced DA responses and chronically as functional toxicity at the DA synapse.
Furthermore, such interactions may contribute to the deleterious effects reported by
bath salt users. Together, these findings have shown that the composition of bath salts
preparations can significantly influence their psychostimulant and toxic effects,
substantiating the importance of modeling bath salts as drug mixtures.
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CHAPTER 1
INTRODUCTION
Defining ‘Bath Salts’ and Related Drugs
The neuropharmacology and toxicology of synthetic compounds marketed as
‘bath salts’ are primary topics of this dissertation. As ‘bath salts’ is a blanket term for
designer drugs mixes containing one or various synthetic cathinones, it is important to
define the synthetic cathinones most commonly found in bath salts as they have been
investigated in this dissertation.
Bath salts – Bath salts have no legitimate purpose as bath additives. This
marketing term refers to designer drug products that are purchased as “legal high”
alternatives to illicit psychostimulant compounds such as cocaine, methamphetamine,
and 3,4- methylenedioxymethamphetamine (MDMA, ecstasy). Bath salts are primarily
sold as powders or fine crystals and are given redolent names such as - “White
Lightning,” “Bliss,” and “Cotton Cloud” – with labels stating “not for human consumption”
or a variant in order to circumvent legislation banning the sale of these psychoactive
substances (Shanks et al. 2012; Spiller et al. 2011). The main psychoactive
components of bath salts are synthetic cathinones.
Amphetamine and amphetamines – Given that the synthetic cathinones are
novel, chemical derivatives of amphetamine, it is helpful to understand this group of
drugs. The chemical structure of amphetamine is presented in Figure 1.1. Amphetamine
(AMPH), or α-methyl-phenethylamine, is chemically defined by Biel and Bopp as a
compound consisting of: 1) an unsubstituted phenyl ring, 2) a two-carbon side chain (α
14

and β carbons) that connects the phenyl ring to nitrogen, 3) an α-methyl group, and 4) a
primary amino group (Biel and Bopp 1978). Various chemical modifications and
functional group substitutions to the amphetamine scaffold have yielded a large number
of amphetamine derivatives. For example, methylation of the amino group and 3,4
methylenedioxy ring substitution onto the phenyl group of amphetamine produce
methamphetamine (METH) and MDMA, respectively (see Fig 1.1). Amphetamine
derivatives have a common phenethylamine backbone and are collectively referred to
as substituted amphetamines or simply amphetamines.
Cathinone and synthetic cathinones – The word cathinone refers to the molecule
referenced in Fig 1.1. Cathinone, the parent compound to synthetic cathinones, is a
naturally occurring phenylalkylamine alkaloid found in the leaves of the khat plant
(Catha edulis). The backbone of cathinone is phenethylamine with a ketone group
substituted on the β carbon. Therefore, cathinones can be referred to as β-keto
amphetamines. As with amphetamine, the amino group of the cathinone can be
methylated (ie methcathinone, Fig 1.1), and functional groups can added to many
locations on the ring and side chain of the molecule, producing various structural
analogs called substituted, or synthetic, cathinones. The compounds mephedrone,
methylone, and MDPV (3,4-methylenedioxypyrovalerone) are examples of such
synthetic cathinones and will be discussed thoroughly. In this thesis, the terms
cathinone(s), and synthetic cathinone(s) will refer to any specific cathinone or the entire
group of cathinones.
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Mephedrone – Mephedrone, 4-methylmethcathinone, consists of a methyl group
attached to the amine, α carbon, and 4’ carbon on the phenyl ring of the β-keto
amphetamine backbone, making it similar in structure to methamphetamine (Fig 1).
Methylone – Methylone, 3,4-methylenedioxymethcathinone, is also methylated
on the amine group and α carbon of the cathinone/β-keto amphetamine backbone, but
differs from mephedrone as it has a 3,4-methylenedioxy ring added to the phenyl ring.
Thus, methylone is structurally similar to MDMA (Fig 1.1).
MDPV – MDPV, 3,4-methylenedioxypyrovalerone, has the largest structural
divergence from cathinone when compared to mephedrone or methylone. MDPV has a
3,4 methylenedioxy ring added to the phenyl ring of the β-keto amphetamine backbone
and a pyrrolidinyl ring and propyl group attached to the α carbon (Fig 1.1), making it
structurally similar to pyrovalerone.
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Figure 1.1 Molecular structures of amphetamine, cathinone, and related compounds
Synthetic Cathinones: History and Abuse
Catha edulis (khat) and the Discovery of Cathinone
While the first written reports of khat use date back to the 14th century, the khat
shrub was not well known by Europeans until its discovery and cataloguing in the 18th
century by botanist Peter Forskal (Karila et al. 2015). Later, advances in analytical
chemistry allowed for the isolation of an active ingredient, identified as ‘katin’ ((+)
norpseudo-ephedrine), from khat extracts in 1887 (Kelly 2011). However, in the 20th
century the United Nations Narcotic Laboratory analyzed khat leaves and confirmed the
presence of another active ingredient, cathinone (Patel 2000). A controlled study
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confirmed that cathinone was the compound responsible for the amphetamine-like
stimulatory effect that accompanied chewing khat leaves (Widler et al. 1994). To this
day, khat shrubs continue to be cultivated in the Arabian Peninsula and specific regions
of Eastern Africa where their leaves are still commonly chewed for their stimulant effects
(De Felice et al. 2014). While the use of khat was localized to these regions in the past,
it became a widespread problem in more recent history following advances in logistics
and immigration as well as invention of the internet (Coppola and Mondola 2012b; Katz
et al. 2014).
Synthesis of Cathinone Analogues
Like many designer drugs, synthetic/substituted cathinones were first
synthesized by academic chemists or the pharmaceutical industry for research or
medicinal purposes. Therefore, synthesis protocols and the associated effects of these
compounds were available in the literature and often discovered and repurposed as
drugs of abuse at later dates (German et al. 2014). The first synthetic cathinone
developed was methcathinone, a methylated analogue of cathinone. It was reportedly
synthesized as an antidepressant in the former Soviet Union in 1928 and separately in
the western world for use as an appetite suppressant in the 1950s (Spiller et al. 2011).
Despite never being marketed due its abuse potential, methcathinone was rediscovered
and used as a drug of abuse in the 1990s. Development of mephedrone, MDPV, and
methylone were first described in 1929, 1967, and 1996 respectively, while their abuse
was not reported until the early- to mid- 2000s and came immediately prior the
classification of cathinone and methcathinone as a schedule I controlled substances
(German et al. 2014).
18

Controlled Substance Legislation and the Development of Designer Drugs
The term “designer drug” refers to the fact that these compounds are specifically
designed to circumvent drug laws. The Controlled Substance Act (CSA) of 1970
established a framework for substances of abuse in the United States (USA), classifying
compounds on a scale from schedule I to V based on medical use and potential for
abuse (Banks et al. 2014). The CSA also permitted federal regulation of the
manufacture, importation, possession, use, and distribution of controlled substances.
This included the psychostimulants, cocaine and amphetamine. However, under this
legislation, the government could not prosecute for the production, possession, or
consumption of controlled substance analogues until those specific compounds were
scheduled. Thus, after the CSA was passed, numerous synthetic designer compounds
surfaced on the drug market and were abused to mimic the effects of popular illicit
drugs, while eluding federal regulation (Banks et al. 2014). The first designer
compounds to emerge were synthetic opioids in 1979, followed by psychostimulant
analogues including methamphetamine and MDMA (German et al. 2014). As the abuse
of designer drugs grew, the CSA was amended in 1986 to include compounds intended
for human consumption that were “substantially similar” to schedule I and II controlled
substances to be treated as schedule I substances. However, to avoid prosecution
under the 1986 Controlled Substance Analogue Enforcement Act, designer drug
analogues that had yet to be specifically scheduled as controlled substances began to
be marketed explicitly as products that were “not for human consumption” (Seely et al.
2013; Spiller et al. 2011; Valente et al. 2014). This tactic was used to launch the
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manufacturing, widespread distribution, and global abuse of synthetic cathinones
without legal consequence.
Prevalence of Synthetic Cathinones and the New Designer Drug Market
Due to structural substitutions to the cathinone (β-keto amphetamine) molecule,
synthetic cathinones were previously not covered by existing drug laws and could
therefore be legally distributed and sold as bath salt products that were “not for human
consumption” (Banks et al. 2014). MDPV, mephedrone, and methylone were the most
commonly identified synthetic cathinones in the forensic analysis of confiscated bath
salts products (DEA 2011; Shanks et al. 2012; Spiller et al. 2011). Given the reported
ability of these compounds to cause similar physical and neuropsychiatric effects as
cocaine, MDMA, and the amphetamines, the abuse of bath salts was popularized under
the notion that they were cheap and ‘legal’ alternatives to these illicit drugs. As a result,
the global abuse of synthetic cathinones dramatically increased within the past decade.
In 2011, the NHS reported that mephedrone was the third most commonly abused drug
in the UK (German et al. 2014), while at the same time the National Forensic Laboratory
Information System (NFLIS) named MDPV and methylone the fifth and eleventh most
common hallucinogens in the US (DEA 2014).
This increase in bath salts popularity has precipitated a concerning rise in the
number of individuals requiring emergency medical treatment after synthetic cathinone
intoxication. Data compiled from the American association of Poison Control Centers
show a dramatic spike in the reports of bath salts overdose from 2009-2012, with the
number of cases exceeding 7000 (Wood 2013). Another retrospective review of poison
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control centers across 9 states found that 16% of reported bath salt toxicities resulted in
either major medical consequences or death (Warrick et al. 2013). Furthermore, the
Substance Abuse and Mental Health Services Administration (SAMHSA) reported that
bath salts were involved in over 22,000 drug-related emergency department visits in
2011 alone. The alarming rise of bath salts abuse and toxicities cases led to the
scheduling of the most commonly abused synthetic cathinones, MDPV, mephedrone,
and methylone, as class I controlled substances in 2011(DEA 2011). However, despite
this classification, international control laws remain lacking and synthetic cathinone
abuse has continued to thrive due in large part to a vast online e-commerce-based
market for these compounds (Karila et al. 2015; Power 2014). In this clandestine
marketplace, bath salts are synthesized, primarily in China and surrounding South East
Asian countries, packaged, distributed, and sold directly to consumers (Katz et al.
2014). As such, it is reported that MDPV, mephedrone, and methylone remain available
in the street drug marketplace where they continue to be abused under false notions
that they are “legal” and “safe” alternatives to more regulated illicit psychostimulants
such as methamphetamine, MDMA, and cocaine (DEA 2014; Seely et al. 2013).
Additionally, as the phenol ring and side chain of these cathinone analogs offer many
possibilities for substitutions, chemists continue to come up with new substituted
cathinones and give them different names in order to replace the banned substances.
Recent reports indicate that over 44 different types of synthetic cathinones have been
encountered worldwide (UNODC, 2013).
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Patterns of Abuse and Drug Combinations
According to numerous drug survey reports, synthetic cathinones are most
popular among youths in urban environments, with adolescent males abusing them
more frequently than females (DEA 2011). There is also an emergence of mid-to-late
adolescents and young adult men abusing bath salts while attending techo-alternative
parties (Zawilska and Wojcieszak 2013). The most common route of synthetic cathinone
administration is insufflation (snorting), but they may also be ingested in the form of
capsules or tablets (DEA 2011; Katz et al. 2014). Less common modalities include
inhalation, intravenous injection, intramuscular injection, and rectal administration (DEA
2011; Zawilska and Wojcieszak 2013). The average amount of synthetic cathinones
abused per session varies widely from 25 milligrams to 5 grams, usually achieved
through repeated doses ranging from 25 to 250 milligrams (DEA 2011).
According to DEA statistics, bath salt preparations are commonly composed of
MDPV, mephedrone, and methylone in combination with each other or other stimulant
compounds (DEA 2014). In support of this, SAMHSA reports that over half of the
registered emergency room visits associated with bath salt intoxication in 2011 involved
synthetic cathinone compounds in various drug combinations (The DAWN Report,
2013). Additionally, analysis of popular ‘legal high’ or ‘bath salts’ brands, as determined
by retrospective searches of records involving synthetic cathinone intoxication at poison
control centers, revealed that many of the most popular bath salt ‘brands’ contained
mixtures of MDPV, mephedrone, and methylone (Araujo et al. 2015; Spiller et al. 2011).
Moreover, in an effort to keep production costs down, clandestine drug manufacturer’s
use these compounds to dilute the purity of MDMA and other illicit drugs (Brandt et al.
22

2010; Brunt et al. 2011; Winstock et al. 2011b). Thus, evidence now indicates that these
compounds are frequently co-abused with each other and various other drug
compounds in order to enhance their desired effects, and it appears likely that
combinations of MDPV, mephedrone, methylone, or their possible analogs will continue
to be found in designer drug mixtures (Coppola and Mondola 2012b; Spiller et al. 2011;
Zawilska and Wojcieszak 2013).
Monoamine Neurotransmitter Systems
The pharmacological actions of synthetic cathinones include modulation of
monoamine neurotransmitters, namely dopamine (DA), norepinephrine (NE), and
serotonin (5-HT). The structural similarities between monoamines and psychostimulant
compounds, including the cathinones, enable these drugs to interact with monoamine
regulatory proteins and dysregulate signaling. Therefore, a brief overview of the
anatomy and functionality of these systems is given.
Dopamine
Dopamine cell bodies are primary found in the substantia nigra (SN) and ventral
tegmental area (VTA) (Björklund and Dunnett 2007; Oades and Halliday 1987).
Dopamine cell bodies in the SN send projections into the striatum (STR, caudate
putamen) and globus pallidus, forming the nigrostriatal brain pathway. This pathway
may also be termed the motor control pathway as it plays an important role in
movement coordination and behavioral sensitization to psychostimulant drugs of abuse
(Björklund and Dunnett 2007; Uhl et al. 2002). Dopamine cell bodies in the VTA send
projections to the limbic system – amygdala, nucleus accumbens (NAc), hippocampus
23

(mesolimbic) – and to areas of the cerebral cortex (mesocortical). The mesolimbic
projection pathway, also termed the reward pathway, plays a central role in the
rewarding effects of naturally rewarding stimuli, such as food and sex, and rewardmotivated behavior (Wise and Rompre 1989). This pathway is also implicated in the
stimulant and rewarding properties of psychostimulant drugs of abuse (Volkow and
Morales 2015; Wise 1996). The NAc is the primary projection site associated with
rewarding stimuli and reference to the mesolimbic(Kelly et al. 2008) system in this
dissertation specifically refers to the VTA to NAc pathway. Dysregulation of DA in the
nigrostriatal and mesolimbic pathways is implicated in psychostimulant drug addiction.
In dopamine neurons, biosynthesis of DA begins with the cytosolic conversion of
tyrosine to dihydroxyphenylalanine (L-DOPA) via the rate limiting enzyme, tyrosine
hydroxylase (TH). L-DOPA is then converted to DA by aromatic L-amino acid
decarboxylase (AADC). DA is sequestered from the cytosol into synaptic vesicles by
vesicular monoamine transporter (VMAT) and stored in vesicles until stimulation. Firing
of an action potential prompts vesicular docking and release of DA into the synaptic cleft
via exocytosis. Released DA binds to and activates dopamine receptors (D1, D2, D3,
D4, D5) on found both postsynaptic and presynaptic neurons (Missale et al. 1998).
Activation of D1- like receptors (D1 and D5) generally produces an excitatory effect,
increasing neurotransmission (Dearry et al. 1990). Moreover, enhanced D1 receptor
activity in the mesolimbic and nigrostriatal pathways has been implicated in behavioral
sensitization and the reinforcing and stimulant properties of psychostimulant drugs of
abuse (Hu et al. 2002; Presti et al. 2003; Uhl et al. 2002). Activation of D2-like receptors
(D2, D3, D4) by released DA reduces neuronal firing in the mesolimbic and nigrostriatal
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brain pathways (Missale et al. 1998). Notably, presynaptic D2 receptors function as
autoreceptors which negatively regulate DA signaling (Beaulieu and Gainetdinov 2011),
and D2 antagonists reportedly decrease the ambulatory response but enhance the
expression of sensitization of many psychostimulants (Mohd-Yusof et al. 2016). After
receptor signaling, DA is taken back up into the presynaptic terminal by the dopamine
transporter (DAT) where it is either recycled and repackaged into synaptic vesicles by
VMAT or degraded by mitochondrial monoamine oxidase B (MAO-B) and catechol-Omethyltransferase (COMT) to produce homovanillic acid (HVA) via the intermediate
metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and 3-methoxytyramine (3-MT).
Serotonin
The cell bodies of serotonin neurons are concentrated in midline areas of the
midbrain and brainstem termed the raphe nuclei (Steinbusch 1981). Axonal projections
are sent upward from the raphe nuclei via the medial forebrain bundle where they form
widespread connections with various targets including the frontal cortex, NAc, STR, and
hippocampus (Baumgarten and Grozdanovic 2000). Serotonin modulates several brain
functions such as satiety, anxiety, emotion, mood, and sleep (Jacobs and Azmitia 1992;
Pum et al. 2009; Ursin 2002). Serotonin biosynthesis begins via the cytosolic
conversion of L-tryptophan to 5-hydroxytryptophan (5-HTP) by the rate limiting enzyme
tryptophan hydroxylase (TPH). 5-HTP is then converted to serotonin, or 5hydroxytryptamine (5-HT), by cytosolic AADC. Serotonin, 5-HT, is then packaged into
vesicles by VMAT and subsequently released into the synapse via exocytosis after an
action potential has fired. Once released serotonin binds to one of 14 serotonin receptor
subtypes found widely expressed throughout the CNS with notable localizations of 525

HT1B,2A,2C,3 in dopaminergic regions (NAc, STR, SN, VTA) (Baumgarten and
Grozdanovic 2000; Egerton et al. 2008). Notably, 5-HT2C receptors are expressed on
inhibitory GABA (γ-aminobutyric acid) neurons in the SN and VTA (Berro et al. 2017; De
Deurwaerdère et al. 2004). Thus, 5-HT activation of these receptors inhibits
downstream DA neurotransmission (Olijslagers et al. 2006). Importantly, given that 5HT2C negatively regulate DA signaling, drugs which promote simultaneous increases in
DA and 5-HT in the NAc (and STR) are subsequently predicted to have lower rewarding
and stimulant properties (Alex and Pehek 2007; Berro et al. 2017). After receptor
signaling, 5-HT is transported back into presynaptic nerve terminals via the serotonin
transporter (SERT), where it is repacked into vesicles by VMAT or degraded by MAO-A
to yield 5-hydroxyindolacetic acid (5-HIAA).
Norepinephrine
Noradrenergic neurons, which synthesize norepinephrine (NE), are most notably
found in the locus coeruleus of the brainstem (von Bohlen und Halbach and Dermietzel
2006). These cells send projections that extend upward via the medial forebrain bundle
where they form a broad range of synaptic contacts with targets in the cerebellum,
cerebral cortex, and thalamic nuclei. Due to the wide distribution of projection sites, NE
cells of the locus coeruleus modulate various behavioral and physiological processes
including altertness, overall arousal, wakefulness and mood (Berridge and Waterhouse
2003). As NE and DA are both catecholamines, their biosynthesis occurs via the same
pathway. Thus, tyrosine is converted to L-DOPA and then to DA by TH and AADC,
respectively. In noradrenergic neurons DA is transported by VMAT into vesicles
containing dopamine-β-hydroxylase (DBH), which subsequently converts DA to NE.
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Following stimulation and exocytosis, NE is released into the synaptic cleft were it
activates adrenergic receptors, which also serve as targets for adrenaline. Two
subtypes of adrenergic receptors have been described: alpha (α1, α2) and beta (β1, β2,
and β3) which are found throughout the CNS and on peripheral targets (Insel 1996). NE
neurotransmitters are taken back up into presynaptic neurons by the norepinephrine
transporter (NET) and is either recycled into synaptic vesicles by VMAT or degraded by
MAO and COMT to yield 3-methoxy-4-hydroxyphenylglycol (MHPG) and
vanillymandelic acid (VMA), respectively.
Monoamine Transporters: DAT, NET, SERT
Dopamine (DAT), norepinephrine (NET), and serotonin (SERT) transporters
terminate DA, NE, and 5-HT neurotransmitter signaling, respectively, via active
reuptake into the presynaptic neuron (Robertson et al. 2009). As monoamine
transporters are members of the solute carrier-6 (SLC6) family of secondary active
transporters, the inward transport of released neurotransmitters (NTs) is driven by the
sequential binding and co-transport of Na+ and Cl- down their electrochemical gradients
(Reith 2002; Torres et al. 2003). The binding of substrate, two Na+ ions, and one Cl- ion
triggers a conformational change in the transporter, shifting it from an “outward-facing”
to an “inward-facing” conformation where the substrate, Na+, and Cl- are released into to
the cytosol (Forrest et al. 2008; German et al. 2015). The release of the
neurotransmitter substrate shifts the transporter from its inward-facing conformation to
its outward-facing conformation. These plasmalemma transporters consist of 12
transmembrane domains and intracellular loop domains containing phosphorylation and
other biding sides that are essential for their regulation and function (Torres et al. 2003).
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Since monoamine transporters regulate the strength and duration of neurotransmitter
signaling many pharmacological agents often target these molecules in order to
manipulate DA, NE, and 5-HT neurotransmission and the biological processes they
modulate (Robertson et al. 2009). Moreover, given the structural similarities of DAT,
NET, and SERT, it is important to note that drug compounds developed to target one of
these transporters may also act on any or all of the other monoamine transporters,
albeit with varying affinity and potency. However, in regards to psychostimulant drugs of
abuse, DAT is a major target and will thus be discussed more thoroughly in this thesis.
Neuropharmacology of Drug Abuse: DAT-Targeting Compounds
The processing of reward-related stimuli, including those affiliated with drugs of
abuse, is primarily mediated by mesolimbic neuronal projections from the VTA to the
NAc (Volkow and Morales 2015; Wise 1996). Amphetamine-derived drugs of abuse
target DAT in the dopaminergic nerve terminal regions, NAc and STR, and produce
characteristic increases in extracellular DA within these regions (Carboni et al. 1989;
Jones et al. 1998; Sitte and Freissmuth 2015). Drug-induced increases in accumbal DA
release mimics phasic firing of VTA neurons and provokes rapid increases in DA
necessary to stimulate D1 receptors (enhanced DA neurotransmission), which
corresponds to the mechanism by which reward is signaled in the brain (Fleckenstein et
al. 2007; Sitte and Freissmuth 2015; Wise 1996). Thus, these drugs are said to have
rewarding properties. Additionally, as the mesolimbic pathway modulates reward
motivated behavior to natural reward stimuli, such as food, this also applies to
rewarding stimuli from drugs of abuse and corresponds to their reinforcing properties
(Koob 1992; Wise 1996). This has been directly shown by studies using the neurotoxin
28

6-hydroxydopamine (6-OHDA), whereby 6-OHDA-induced lesions of the NAc resulted in
prolonged, significant decreases in the reinforcing effects of cocaine (selfadministration) (Roberts and Koob 1982).
In addition, amphetamine-like stimulants of abuse increase locomotor activity. A
specific role for extracellular DA and DAT in this behavioral response has come from
studies using DAT knockout mice, whereby DAT deficient animals were unresponsive to
the stimulant effects of cocaine and amphetamine and did not show DA elevations
following administration of these psychostimulants (Giros et al. 1996; Tilley et al. 2009).
Also, neurotoxin-induced lesions of the NAc in rats abolished the psychostimulantinduced locomotor activity of amphetamine and cocaine, specifically implicating a role
for mesolimbic DA in these responses (Kelly and Iversen 1976; Kelly et al. 1975).
Moreover, investigations using microdialysis have shown that the extent of drug-induced
DA elevations in the NAc positively correlate with the motor-stimulant effect of abused
psychostimulant compounds (Benwell and Balfour 1992; Bradberry 2002; Bradberry et
al. 1991; Pierce and Kalivas 1995).
Repeated, intermittent exposure to stimulant drugs of abuse often enhances the
motor-stimulant response over time, a phenomenon termed behavioral sensitization
(Pierce and Kalivas 1997). This process involves activation of the mesolimbic and
nigrostriatal DA systems and can be manifested as increased locomotor activity or
increased stereotyped behavior (repetitive or patterned movement) (Budygin et al.
2000; Robinson and Becker 1986; Steketee and Kalivas 2011; Vanderschuren and
Kalivas 2000). Amphetamine-like stimulants often display a biphasic pattern of activity,
whereby these drugs produce sensitized hyperactivity at lower doses, while sensitized
29

stereotyped activity is reported with very high doses (Kuczenski and Segal 1997; Pierce
and Kalivas 1995). It is now accepted that mesolimbic DA plays a key role in the
development of behavioral sensitization. Initial evidence for this came from studies
showing that the expression of behavioral sensitization could be induced by intracranial
injections of amphetamine into the VTA and NAc (Carr and White 1987). Moreover,
striatal DA has been primarily implicated in the induction of stereotypic activity. A
specific role for the nigrostriatal system in the induction of stereotypic activity was
deduced from the observations that intrastriatal injections of amphetamine and DA
produced stereotypy in rodents (Kelley et al. 1988; Presti et al. 2003), while 6-OHDAinduced lesions of the substantia nigra and striatum prevented amphetamine-induced
stereotypy (Joyce and Iversen 1984; Price and Fibiger 1974).
Mechanism of Transporter Interaction: Monoamine Releasers and Reuptake Inhibitors
Monoamine transporters serve as primary biological targets for many drugs of
abuse and pharmaceuticals (Amara and Sonders 1998). Pharmacological agents that
interact with monoamine transporters can be divided into two functionally distinct
classes: 1) pure monoamine reuptake inhibitors and 2) monoamine releasers or
substrates (Baumann et al. 2014; Rothman and Baumann 2003). In addition, a
distinguishing property of a given monoamine reuptake inhibitor or releaser compound
is its relative potency at DAT, NET, and SERT or transporter selectivity profile.
Monoamine reuptake inhibitors act as competitive blockers that bind monoamine
transporters and prevent transporter-mediated reuptake of synaptic DA, NE, and/or 5HT into presynaptic terminals following their action potential –dependent release
(Rothman and Baumann 2003). Cocaine is an example of a widely abused reuptake
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inhibitor and its action to selectively bind DAT and block the DAT-mediated reuptake of
DA from the synaptic cleft is well-documented (Boja and Kuhar 1989; Johanson and
Fischman 1989; Jones 1984; Ritz et al. 1990). In contrast, monoamine releasers
behave as substrates at monoamine transporters, competing with endogenous NTs for
transporter-mediate uptake into the presynaptic neurons (Fleckenstein et al. 2007; Sitte
et al. 1998). Once actively transported into neurons, these compounds promote the
release of DA, NE, and/or 5-HT back into the synapse via reversal of monoamine
transporter flux (Jones et al. 1999; Rothman and Baumann 2003). Most amphetamines,
including METH and MDMA, are substrate-type releasers. Specifically, METH is a
selective substrate for DAT-mediated transport into presynaptic neurons and
subsequently induces DAT-mediated reverse transport of DA into the synaptic cleft
(Calipari and Ferris 2013; Fleckenstein et al. 2007; Jones et al. 1999). MDMA (ecstasy)
is also a transporter substrate, however, the methylenedioxy ring on MDMA results in a
compound with a nearly 10-fold greater affinity for SERT as compared to METH
(Eshleman et al. 2013; Rudnick and Wall 1992), while its effects at DAT are significantly
weaker. Thus, MDMA is a non-selective transporter substrate and promotes the release
of both 5-HT and DA, albeit with 5-HT release exceeding that of DA (Gudelsky and
Nash 1996).
The mechanism by which amphetamine-like compounds promote transportermediated efflux involves a concerted action of these drugs to inhibit MAO and disrupt
VMAT function upon neuronal entry (Schmitz et al. 2001; Sitte and Freissmuth 2015).
Amphetamines are also exogenous substrates of VMAT, and thus, accumulate in
synaptic vesicles (Sulzer et al. 1995). Therein, the amphetamines act as weak bases in
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the acidic luminal environment of synaptic vesicles and dissipate the proton gradient.
This prevents the inward transport of monoamines by VMAT and results in an elevation
of monoamines in the cytosol (Gulaboski et al. 2007; Sulzer and Rayport 1990), which
is further exacerbated by MAO inhibition (Sitte and Freissmuth 2015; Thomas et al.
2008). Thus, the amphetamines increase cytosolic monoamine concentrations to levels
that allow for occupation of their internal binding site on plasmalemma transporters and
subsequently their outward transport (Sulzer et al. 1993). Notably, elevations in
cytosolic DA levels have been attributed to the neurotoxicity of METH and other
amphetamine-related drugs.
Neurotoxicology of Amphetamine-Related Drugs
Dopaminergic brain regions are the primary targets of neurotoxicity induced by
amphetamine-related drugs (Yamamoto et al. 2010). Neurochemical markers of this
toxicity include decreased DA and DA metabolite tissue content and decreased
expression levels of TH and DAT, all of which have been observed in the striatum (STR)
and frontal cortex with very high single doses or repeated doses of METH and AMPH
administration (Halpin et al. 2014; Moratalla et al. 2017; Wagner et al. 1980). Most
importantly, METH and AMPH produce long term damage to dopamine axon terminals
in the STR (Ares-Santos et al. 2014; Granado et al. 2011; Ricaurte et al. 1982), while
reducing the number of TH-positive nissl stained neurons in the substantia nigra pars
compacta (SNpc) (Ares-Santos et al. 2014). Additionally, the amphetamines trigger
neuroinflammatory responses in the brain areas most affected by their toxicity (Thomas
et al. 2004).
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Biochemical Mechanisms of Neurotoxicity: Oxidative Stress and Excitotoxicity
The mechanisms underlying METH and AMPH-mediated neurotoxicity are
complex and may involve several different processes. In this regard, oxidative stress is
thought to be a key mechanism, given that METH and AMPH increase the production of
reactive oxygen species (ROS), such as hydroxyl radicals and superoxides, and
reactive nitrogen species (RNS), such as nitric oxide (NO) and peroxynitrite (Cadet and
Brannock 1998; Cubells et al. 1994; Hansen et al. 2002). ROS and RNS can damage
membranes, inhibit protein function, and damage DNA (Cadet and Brannock 1998).
Further support for the involvement of oxidative stress in amph-induced DA toxicity was
provided by studies showing that meth and MDMA-induced DA depletions were
attenuated by antioxidant treatment (N-acetyl-cysteine, ascorbic acid, and vitamin E)
(De Vito and Wagner 1989; Fukami et al. 2004; Wagner et al. 1986) and exacerbated
following glutathione depletion and inhibition of both superoxide dismutase and nitric
oxide synthase (NOS) (Brown and Yamamoto 2003; Jayanthi et al. 1998). Several
mechanisms contribute to the formation of ROS and RNS following exposure to
amphetamine-related dugs via several mechanisms.
Reactive metabolites of DA degradation are considered a primary source of ROS
in amphetamine-induced oxidative stress (Delcambre et al. 2016; Fleckenstein et al.
2007; Schmidt et al. 1985; Yamamoto and Bankson 2005). Amphetamine-related drugs
increase the cytosolic pool of DA available for 1) metabolism by MAO to yield DOPAC
and hydrogen peroxide and 2) direct oxidation to form DA semiquinones and superoxide
radicals. Hydrogen peroxide and superoxide anions can generate highly reactive
hydroxyl radicals via fenton reactions (Kuhn et al. 2006; LaVoie and Hastings 1999).
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Hydroxy radicals damage various cellular components and initiate lipid peroxidation,
leading to membrane damage (necrosis), and eventually activate proteases, initiating
the cell death cascade (Cadet et al. 2005). Support for the involvement of DA in METH
and AMPH-induced toxicity comes from studies showing that inhibition of DA synthesis
afforded neuroprotection (Ares-Santos et al. 2012; Larsen et al. 2002; Schmidt et al.
1985), while increasing cytosolic DA levels with DA precursor, l-dopa, exacerbated
these toxic effects (Gibb and Kogan 1979; Schmidt et al. 1985).
Additionally, METH and AMPH induce oxidative stress by enhancing glutamate
release (Mark et al. 2004; Nash and Yamamoto 1992). This process, termed
excitotoxicity, culminates in increased cytosolic Ca2+ and leads to the formation of RNS
and ROS (Forder and Tymianski 2009). Specifically, NO, which is produced
subsequent activation of the Ca2+-dependent nNOS, readily reacts with superoxide
anions to form highly reactive peroxynitrite compounds that produce toxicity via the
nitrosylation of proteins (Bruno et al. 1993). Evidence for the involvement of this process
in METH and AMPH neurotoxicity has been provided by several studies demonstrating
that blockade of nNOS and glutamate receptor activity provides full protection against
AMPH-induced DA depletion (Chipana et al. 2008; Itzhak et al. 2000; Mark et al. 2004),
and others showing that co-administration of METH with peroxynitrite scavengers
partially prevented this toxic effect (Imam et al. 2000). Moreover, robust elevations in
extracellular DA produced by binge doses of METH have been directly implicated in the
development of excitotoxicity, whereby excessive DA release activates the nigrostriatal
pathway and causes increased striatal glutamate release (Brown et al. 2005; Halpin et
al. 2014; Mark et al. 2004). Another consequence of excitotoxicity is inhibition of
34

complex II of the mitochondrial electron transport chain by peroxynitrite, resulting in
excessive leakage of ROS in addition to altered energy metabolism (Heales et al.
1999). Indeed, METH-induced striatal DA depletions were accompanied by decreased
complex II activity and exacerbated by the complex II inhibitor, malonate (Brown et al.
2005). Also, inhibition of complex II activity was shown to be dependent on glutamate
receptor activation and peroxynitrite formation (Brown et al. 2005). Moreover, METHinduced mitochondrial dysfunction is suggested to mediate the long-term deficits in DA
and DA regulating proteins produced by the amphetamines (Yamamoto et al. 2010).
Neuroinflammation
Glial cells (astroglia and microglia) modulate the neuroinflammatory response in
the CNS by releasing pro-inflammatory cytokines following brain insult (Lucas et al.
2006). Over activation of this response, as observed with various neurodegenerative
conditions, causes persistent neuroinflammation and eventually contributes to the loss
of neurons (Lucas et al. 2006). Thus, reactive gliosis is considered a universal reaction
to injury in the CNS and is often used as a marker of neuronal damage (O’Callaghan
and Sriram 2005). Biochemical markers of gliosis include the increased expression of
glial fibrillary acidic protein (GFAP) and the ionized calcium-binding adaptor protein-1
(Iba1), which is indicative of astroglia and microglia activation, respectively. Notably,
several studies have shown that AMPH-related compounds increase GFAP and Iba1
immunoreactivity in the STR, cortex, and SNpc; areas that are most affected by METH
and AMPH-mediated neurotoxicity (Ares-Santos et al. 2013; Granado et al. 2011;
Guilarte et al. 2003; Thomas et al. 2004). While the mechanism behind this response is
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not well elucidated, DA quinones and glutamate receptor activation have also been
shown to stimulate microglia activation (Kuhn et al. 2006).
Determining the Pharmacology of Novel Drugs
As monoamine transporters are symporter proteins, they express the
electrogenic properties of ion channels (Alexander et al. 2011). Thus, molecules that
interact with these proteins, including their endogenous substrates DA, NE, and 5-HT,
induce transporter-mediated ionic currents that can be measured using voltage clamp
techniques in cells stably expressing human monoamine transporters (Torres et al.
2003). Specifically, compounds that are translocated through transporters into neuronal
cells along with sodium ions produce transporter-mediated inward (depolarizing)
currents, while compounds that bind to transporters but are not translocated into cells
produce outward currents (due to blockade of an endogenous leak current) (Alexander
et al. 2011). Therefore, the action of a drug at monoamine transporter proteins can be
determined by measuring these ionic currents in cells before and after drug exposure.
For novel drug compounds, the nature and selectivity of their interactions with
monoamine transporter can be evaluated using in vitro radioligand uptake and release
assays. In these assays, drugs are analyzed for their potencies and efficacies to (a)
block the uptake of radio-labeled monoamines dispensed in the external solution (IC50
values) or (b) promote release of preloaded radiolabeled monoamine tracers (EC50
values) at specific monoamine transporters (Rothman and Baumann 2003). Pure
reuptake inhibiting compounds block the uptake of radio-labeled monoamines without
evoking full release of preloaded substrates. Monoamine releasing or substrate
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compounds block the reuptake radiolabeled monoamines while also stimulating the full,
efficacious release of preloaded substrates (Baumann et al. 2012; Rothman and
Baumann 2003). Measured IC50 and/or EC50 values reflect the relative potency and
selectivity of a given drug at DAT, NET, and SERT. However, given the complexity of
biological matrices, in vitro analyses do not always accurately represent the in vivo
effects of a drug (De Felice et al. 2014). Thus, in order to characterize the in vivo
neurochemical profiles of a CNS-active drug, high performance liquid chromatography
equipped with electrochemical detection (HPLC-ECD) assays are utilized to measure
the impact of a given drug on endogenous monoamine levels in discrete brain tissue
and cerebral spinal fluid.
The transporter selectivity profile and neurochemical effects of a given
psychostimulant can be used to predict its behavioral effects and abuse potential
(Baumann et al. 2014). For example, as the dopaminergic system is widely accepted to
play a critical role in abuse-related effects, the potency and efficacy of a drug at DAT to
enhance DA signaling, is often associated with its potential for abuse. Drug-induced
elevations in mesolimbic DA are also correlated with elevations in locomotor activity
responses in addition to rewarding properties. Furthermore, given that serotonin
signaling can negatively regulate the release of DA, relative activity of a drug at SERT
can also serve as an indicator of low abuse liability (Howell and Cunningham 2015;
Howell and Kimmel 2008; Rothman and Baumann 2003).

37

Abuse Liability Testing for Novel Drugs
Abuse liability testing utilizes behavioral assays to investigate whether a novel
drug has stimulatory, rewarding, and/or reinforcing properties that are characteristic of
addictive drugs (Balster and Bigelow 2003; FDA 2016). The motor-stimulant effect of a
drug is an indicator of abuse lability and is commonly assessed by monitoring for a
drug’s ability to induce locomotor activity and express behavioral sensitization.
Additionally, a test drug may be assessed for its ability to cross-sensitize with known
drugs of abuse, whereby animals repeatedly administered the novel drug display
enhanced locomotor responses to a challenge dose of cocaine, METH, or MDMA.
Cross-sensitization is thought to occur when two drugs have overlapping mechanisms
that underlie the development of sensitization, despite having distinct transporter
interactions (Steketee and Kalivas 2011). Direct abuse liability studies evaluate whether
a drug has rewarding and/or reinforcing properties using the following behavioral
paradigms: conditioned place preference (CPP), intracranial self-stimulation (ICSS), and
self-administration (Ator and Griffiths 2003). In these assays, the degree of reward
and/or reinforcement of a test drug corresponds to its efficacy and potency to produce
drug side preference, facilitate low rates of self-stimulation, and induce selfadministration in trained animals.
Another approach is to characterize the behavioral effects of a novel drug in
comparison to those of a well-known drug of abuse (Balster and Bigelow 2003; FDA
2016). To this end, drug discrimination assays are used to determine if a test drug
produces descriptive stimulus effects that are similar to those produced by established
drugs of abuse (Ator and Griffiths 2003). In these tests, novel drugs are assessed for
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their ability to produce appropriate responses (full substitution/generalization) in animals
trained to discriminate a known drug of abuse (Berquist and Fantegrossi 2017).
Moreover, compounds that can fully substitute for a specific drug of abuse are thought
to have similar pharmacological activity, subjective effects, and addictive properties as
the comparator drug (Balster and Bigelow 2003; Berquist and Fantegrossi 2017). In
addition, specific behavioral responses elicited by a test drug (e.g. degree of motor
activity and rate of self-administration) can be directly compared to those observed with
known drugs of abuse. Thus, the abuse potential of a novel drug may also be defined in
terms of the likeness or unlikeness of their behavioral responses relative to known
drugs of abuse.
Neuropharmacology of the Synthetic Cathinones
Prior to the emergence of ‘bath salts’ abuse in 2010-2011, scientific literature
regarding the pharmacology of synthetic cathinones was extremely limited. Thus, the
growing prevalence of their abuse in recent years has prompted a number of preclinical
investigations. Specific emphasis has been placed on elucidating the neurochemical,
behavioral, and potential toxic effects of the three most commonly abused synthetic
cathinones, MDPV, mephedrone, and methylone. Therefore, the terms ‘synthetic
cathinone(s),’ ‘cathinone derivative(s),’ and ‘cathinone(s)’ used in the remainder of this
dissertation refer to these three compounds unless otherwise noted.
Initial preclinical investigations of synthetic cathinones evaluated the in vitro
mechanism of action and relative potency of these drugs at monoamine transporters
(Baumann et al. 2012; Eshleman et al. 2013; Simmler et al. 2013). Given the novelty of
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these compounds, many studies have included cocaine and various amphetamine
derivatives as comparator compounds and describe the actions of the synthetic
cathinones in regards to their likeness or unlikeness to these comparator drugs
(Baumann et al. 2012; Baumann et al. 2013). Moreover, as discussed above,
behavioral assays are also used to characterize the subjective stimulus and reinforcing
properties of the synthetic cathinones in comparison to established drugs of abuse
(Gregg and Rawls 2014). Therefore, the use of known comparator compounds
enhances the translation of preclinical data on synthetic cathinones into clinically useful
information.
MDPV
Initial preclinical investigations utilized various in vitro assays to determine the
mechanism of action of MDPV at monoamine transporters. In these studies, MDPV
displayed high affinity binding at DAT and NET, potently blocking the uptake of [3H]-DA
and [3H]-NE, and evoking partial, low efficacy release of preloaded DAT and NET
substrates, while producing only weak effects at SERT (100-fold greater potency at DAT
and NET vs SERT) (Baumann et al. 2013; Eshleman et al. 2013). Additional in vitro
studies reported no significant affinity of MDPV for non-transporter sites of action
(Eshleman et al. 2013; Simmler et al. 2013). Thus, the action of MDPV to selectively
block DAT and NET reuptake, without inducing the transporter-mediated release of DA
and NE suggested that this compound was a cocaine-like, catecholamine reuptake
inhibitor rather than a transporter substrate. Electrophysiology studies showing that
MDPV produces outward, hyperpolarizing currents at hDAT, as seen with cocaine,
confirmed this notion (Cameron et al. 2013a). However, direct comparisons with
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cocaine revealed significant differences in regard to potency and selectivity for
catecholamine transporters. Specifically, MDPV was 50-times more potent at the DAT
and 10-times more potent at the NET than cocaine (Baumann et al. 2013). Taken
together, these studies indicate that MDPV is potent and selective inhibitor of DAT and
NET, and it does not significantly interact with SERT nor does it have non-transporter
sites of action.
In vivo pharmacology of MDPV. In agreement with in vitro findings, MDPV
produced significant dopaminergic effects in vivo. MDPV administration resulted in a
dose-dependent increase in extracellular DA and not 5-HT in both rats (Baumann et al.
2013) and mice (Fantegrossi et al. 2013) in various brain regions as determined by
HPLC-ECD, consistent with its selective inhibition of DA uptake. Moreover, MDPVinduced elevations in dialysate DA in the NAc were 10-fold greater than those found
with cocaine and found to be positively correlated with the extent of locomotor activation
(Aarde et al. 2013c; Baumann et al. 2013). Several studies have reported simulation of
locomotor activity and stereotypy following MDPV treatment (Aarde et al. 2013b;
Fantegrossi et al. 2013; Glennon and Young 2016; Marusich et al. 2012), and some
reported that MDPV-induced increases in ambulation and stereotypic movements were
at least 10 fold greater than cocaine. Interestingly these locomotor effects and could be
attenuated following pretreatment (Baumann et al. 2013; Marusich et al. 2012) with D1
receptor antagonists (Marusich et al. 2014). The psychostimulant effect of MDPV has
been assessed across a range of doses (0.3 – 40 mg/kg), and the dose-response
relationship for ambulatory activity is that of an inverted U-shape curve, with
sensitization of ambulatory activity at lower does (1-10 mg/kg) (Baumann et al. 2016;
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Gregg and Rawls 2014) and significantly reduced ambulation at higher doses of MDPV
(15-30 mg/kg) (Baumann et al. 2016; Fantegrossi et al. 2013). The high dose effect
appears to be due to the manifestation of focused stereotyped behavior (Fantegrossi et
al. 2013; Marusich et al. 2012). Overall, these data indicate that MDPV-mediated
inhibition of DAT increases extracellular DA in mesolimbic brain regions, and that this
enhanced DA neurotransmission is responsible for the stimulant effects of MDPV.
Abuse liability: MDPV. In drug discrimination studies, MDPV fully substituted for
cocaine (Gatch et al. 2013), METH (Fantegrossi et al. 2013), and AMPH (Harvey et al.
2017), but only partially for MDMA (Harvey and Baker 2016), indicating that this
compound produces subjective effects similar to established DA-selective drugs of
abuse. Various studies have demonstrated that MDPV elicits conditioned place
preference (Iversen et al. 2014; Karlsson et al. 2014; King et al. 2015), resulting in a
greater preference score than amphetamine (Karlsson et al. 2014), lowers ICSS
thresholds (Bonano et al. 2014), and is readily self-administered (Aarde et al. 2013b;
Marusich et al. 2012; Schindler et al. 2016b). Based on these data, MDPV may have
greater abuse potential than METH or cocaine.
Mephedrone and Methylone
In contrast to MDPV, mephedrone and methylone appear to be substrates at
monoamine transporters. Several groups have reported that mephedrone and
methylone inhibit the uptake of [3H]-DA and [3H]-NE and [3H]-5-HT (Baumann et al.
2012; Eshleman et al. 2013; Simmler et al. 2013) and stimulate full, efficacious release
of preloaded substrates of DAT, NET, and SERT (Baumann et al. 2012; Eshleman et al.
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2013), with a potency rank of NET>DAT>SERT for mephedrone and NET>SERT>DAT
for methylone. Notably, methylone was found to be half as potent as mephedrone at all
transporters (Baumann et al. 2012). These findings indicate that mephedrone and
methylone induce non-selective substrate activity at all plasmalemma monoamine
transporters, similar to MDMA and AMPH (Cadet et al. 2007; Kalant 2001). Definitive
confirmation of their substrate activity came from studies demonstrating that
mephedrone and methylone produced inward, depolarizing currents at hDAT that are
indicative of a transportable substrate similar to those observed with the amphetamines
(Cameron et al. 2013a; Solis 2016). In comparison studies, mephedrone’s values for
binding affinity, inhibition of uptake, and drug-induced release of preloaded substrates
at DAT and SERT were similar to METH and MDMA values, respectively (Baumann et
al. 2012; Simmler et al. 2013), while methylone displayed weaker DA effects than
METH but promoted 5-HT release similar to MDMA (Baumann et al. 2012). One point of
divergence from METH and MDMA was that both substrate cathinones were less potent
at inhibiting uptake and inducing release of radio-labeled substrates via VMAT2
(Eshleman et al. 2013). Overall, these findings show that mephedrone and methylone
are substrates for all monoamine transporters with non-selective releasing actions that
are similar to MDMA and the amphetamines.
In vivo pharmacology of mephedrone and methylone. The in vivo neurochemical
profiles of mephedrone and methylone are consistent with in vitro findings. Through
microdialysis studies, investigators have determined that mephedrone and methylone
produced dose-related concurrent increases in extracellular DA and 5-HT levels in the
NAc (Aarde et al. 2013a; Baumann et al. 2012; Kehr et al. 2011; Schindler et al. 2016b),
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and mephedrone was more potent than methylone (Baumann et al. 2012; López‐Arnau
et al. 2012). Consistent with the neurochemical effects of MDMA, the majority of HPLC
analyses with mephedrone and methylone have found that the 5-HT increases are
greater in magnitude than the accompanying DA increases (Baumann et al. 2012; Kehr
et al. 2011; López‐Arnau et al. 2012). However, while the ratio of DA: 5-HT release
mimics that of MDMA, the substrate cathinones appear to have greater dopaminergic
effects with potencies resembling AMPH (Kehr et al. 2011). For example, mephedrone
increased dialysate DA in the NAc to levels that were significantly greater than those
produced by MDMA and comparable to amphetamine DA levels (Hadlock et al. 2011;
Kehr et al. 2011). A few studies have reported that mephedrone and methylone produce
dose-dependent increases in locomotor activity (Baumann et al. 2012; Lisek et al. 2012;
Shortall et al. 2013), with mephedrone being the more potent compound (Baumann et
al. 2012; Gregg and Rawls 2014), further implicating enhanced DA neurotransmission
as an effect of these drugs. Like MDPV, sensitization to high doses of mephedrone (1530 mg/kg) is expressed as increased stereotypy (Gregg et al. 2013a), while this effect
was not observed with methylone. Moreover, mephedrone-induced hyperactivity is
attributed to increased striatal levels of DA and 5-HT and appears to be regulated by DA
receptor signaling (Lisek et al. 2012), given that it was attenuated by D1R antagonists
and enhanced by D2R antagonists. Additionally, at least one group has shown that
mephedrone pretreatment cross-sensitizes with motor-stimulant effect of cocaine
(Gregg et al. 2013b). However, the psychostimulant effects of mephedrone and
methylone are more rapid in onset, shorter in duration, and considerably weaker than
those of cocaine, MDPV, or METH (Gatch et al. 2013; Green et al. 2014; Marusich et al.
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2012; Nguyen et al. 2016). Given the significant serotonergic effects of the substrate
cathinones, this is most likely due to 5-HT modulation of dopaminergic effects.
Abuse liability: mephedrone and methylone. In drug discrimination studies,
mephedrone and methylone fully substituted for MDMA, METH, and cocaine (Bonano et
al. 2014; Gatch et al. 2013; Gregg and Rawls 2014), suggesting that these compounds
produce similar subjective effects as these popular drugs of abuse and thus pose a high
potential for abuse. Mephedrone and methylone induced conditioned place preference
and lowered ICSS thresholds, with an ordered potency for both assays reported as
MDPV > mephedrone > methylone (Bonano et al. 2014; Gregg and Rawls 2014;
Karlsson et al. 2014). Moreover, mephedrone and methylone are self-administered by
rodents across multiple doses (Aarde et al. 2013a; Creehan et al. 2015); however, selfadministration of these substrate cathinones took longer to develop than MDPV selfadministration (Schindler et al. 2016b). Overall, mephedrone and methylone produce
rewarding and reinforcing effects in animals that clearly indicate their abuse potential in
humans.
Neurotoxicity of Substrate Cathinones
AMPH and METH have been established to induce neurotoxic damage to DA
neurons in rats and mice (Yamamoto et al. 2010). Given the close structural similarities
and mechanistic overlap of mephedrone and methylone with METH, preclinical research
hypothesized that these compounds may also be neurotoxic to DA nerve endings. In
vitro cytotoxicity assays supported this notion, demonstrating that mephedrone
increases the release of lactate dehydrogenase (associated with disruption of cellular
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membranes) (den Hollander et al. 2014), decreases mitochondrial respiration (den
Hollander et al. 2015), and dose-dependently decreases cell viability superior to that of
MDMA in neuroblastoma cell lines and primary cultures of cortical neurons (MartinezClemente et al. 2014). However, a number of studies have established that neither
mephedrone nor methylone induced blatant toxicity to DA nerve endings (Angoa-Perez
et al. 2012; Angoa-Pérez et al. 2016), as indicated by a lack of persistent decreases in
DA, TH expression, or DAT protein levels. Additionally, no signs of microglial or
astrogilal activation were observed in the striatum 2 or 7 days following binge dosing of
either mephedrone or methylone (Angoa-Perez et al. 2012; Anneken et al. 2015). While
one group has reported prolonged decreases in TH and DAT expression in the frontal
cortex and reduced striatal D2R with repeated mephedrone treatment, doses used in
this study were extremely high (50 mg/kg), and repeated daily doses of this magnitude
would likely result in cardiovascular toxicity that would outweigh neurotoxic effects
(Lopez-Arnau et al. 2015). Moreover, while a few studies have reported mild
serotonergic toxicity with the substrate cathinones when administered at elevated
ambient temperatures (López-Arnau et al. 2014; Martinez-Clemente et al. 2014), followup studies have been conflicting with many groups unable to reproduce this toxicity
(Angoa-Pérez et al. 2014; Miner et al. 2017).
Significant Combined Effects
Interestingly, while mephedrone or methylone do not appear to induce DA toxicity
on their own, they exacerbate the neurotoxic effects of METH and MDMA. When coadministered with neurotoxic doses of METH or MDMA, mephedrone and methylone
significantly decreased striatal DA, DAT, and TH levels and increased GFAP expression
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beyond the effects of METH or MDMA alone (Angoa‐Pérez et al. 2013; Anneken et al.
2015). In contrast, MDPV provided complete protection against the toxic effects of
METH on DA nerve ending markers and GFAP, most likely via its potent and
competitive blockade of DAT-mediated transport (Anneken et al. 2015). While this
neuroprotective effect could be predicted to extend to other DAT substrate drugs, this
does not appear to be the case. Recent studies have reported that self-administration of
binary mixtures of MDPV and methylone resulted in a high incident of lethality (50%)
(Gannon et al. 2018), which was not observed with self-administration of either drug
alone at identical doses. While the pharmacology underlying this combined toxicity has
not been thoroughly investigated, drug-drug interactions at the DAT may be a
contributing factor. A study utilizing in vitro electrophysiology techniques found that
when MDPV and mephedrone were simultaneously applied to the DAT, the substrate
activity of mephedrone (inward current) occurred more quickly than the blocking action
of MDPV (outward current) (Cameron et al. 2013b). This suggests that coadministration of MDPV and mephedrone would first produce DA release via
mephedrone and that DA reuptake would be subsequently prevented due to DAT
blockade via MDPV. Another study demonstrated locomotor sensitization to mixtures of
MDPV and mephedrone and found that rats pretreated with MDPV and mephedrone
displayed cross-sensitization to the locomotor stimulant effects of cocaine, with activity
counts greater than controls and the saline-cocaine group (Berquist et al. 2016).
Additionally, prior exposure to mephedrone increased the stimulant effects of cocaine
(Gregg et al. 2013b). Given the involvement of midbrain dopaminergic circuits in the
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development of sensitization, these studies provide further evidence for augmented DA
neurotransmission by drug combinations containing synthetic cathinones.
Summary and Rationale for the Present Study
The synthetic cathinones, MDPV, mephedrone, and methylone gained worldwide
notoriety as the psychoactive components of ‘bath salts;’ a marketing term used to
circumvent federal drug laws and permit their legal sale. To date, the majority of
preclinical investigations on MDPV, mephedrone, and methylone have primarily focused
on the individual pharmacology and abuse-related effects of these drugs. However,
DEA statistics and forensic reports indicate that bath salt products generally contain
various mixtures of synthetic cathinones (DEA 2011; Spiller et al. 2011). Moreover, a
retrospective search of records involving synthetic cathinones at poison control centers
revealed the most frequently abused bath salt ‘brands,’ identified by patient history
reports, contained binary and ternary mixtures of MDPV, mephedrone, and methylone
(Spiller et al. 2011; Warrick et al. 2013). Therefore, the primary aim of this dissertation
was to address this limitation and provide acuity into the pharmacological interactions
that may occur when these compounds are abused in combination. Our central
hypothesis was that pharmacological interactions at the DAT following co-exposure to
MDPV, mephedrone, and methylone will produce significant short- and long-term effects
on dopaminergic tone. This hypothesis was tested in Chapters 3 and 4, which utilized a
novel HPLC-ECD assay developed in our laboratory for sensitive detection of
monoamines and respective metabolites in the small DA nuclei (VTA and SNpc), in
addition to the larger nerve terminal areas (NAc and STR). The development and
validation of this method is discussed in Chapter 2.
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The individual pharmacological mechanisms of MDPV, mephedrone, and
methylone have been largely determined and suggest opportunities for significant
pharmacological interactions at the DAT. Similar to cocaine, MDPV acts as a highly
selective reuptake inhibitor at DAT and promotes dose-dependent increases in
extracellular DA levels (Baumann et al. 2013; Coppola and Mondola 2012a).
Mephedrone and methylone possess similar pharmacology to METH and MDMA, acting
as non-selective substrates at the DAT, inducing the transporter-mediated release of
DA (Baumann et al. 2012; Simmler et al. 2013). Investigations using in-vivo
microdialysis have indicated that these substrate-type synthetic cathinones precipitate
rapid and marked elevations in dialysate DA levels that are greater than MDMA and
comparable to those observed with METH (Kehr et al. 2011). Given that synergistic
drug-drug interactions are often more profound when the drugs administered produce
qualitatively similar effects via distinct pharmacological mechanisms (Tallarida 2011),
the dichotomy of DAT interactions by MDPV (blocker) and the substrate cathinones to
increase extracellular DA levels provides an avenue for accentuated dopaminergic
effects when these drugs are co-abused.
Chapter 3 of this dissertation has explored the acute effect of co-synthetic
cathinone exposure on DA neurotransmission in mice. This was accomplished using our
novel and validated HPLC-ECD assay (Allen et al. 2017) to measure DA and DA
metabolite levels in discrete brain regions of mice treated with MDPV, mephedrone, and
methylone alone and in combination. In addition, locomotor activity was assessed in
mice treated with the synthetic cathinones individually and in combination to determine
if any combined effects extended to DA-mediated behavioral processes. We
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hypothesized that the co-administration of MDPV, mephedrone, and methylone would
enhance the dopaminergic effects of the individual drugs. From this study, we found a
significant combined effect on both DA levels and locomotor activity that appeared to be
a result of synergistic pharmacological activity. Moreover, this study was the first to
report an in vivo synergistic effect with ternary synthetic cathinone mixtures and
emphasized the importance of using drug mixtures to model bath salts in abuse in
behavioral and neurotoxicity studies.
While interactions between the synthetic cathinones themselves are not well
documented, evidence of a combined pharmacological effect between the substrate
cathinones and neurotoxic DAT-targeting drugs has been reported (Angoa-Pérez et al.
2016). Despite structural and mechanistic similarities to well-known agents of
neurotoxicity, neither mephedrone nor methylone have been shown damage DA nerve
endings; however, both compounds exert the deleterious effect of enhancing METH and
AMPH toxicity when co-administered with these drugs (Angoa-Perez et al. 2012;
Anneken et al. 2015). Given the involvement of elevated DA levels in METH-induced
neurotoxicity via degradation to reactive metabolites and enhancement of glutamatemediated excitotoxicity, the authors of these papers proposed that the substrate
cathinones exacerbated METH toxicity by increasing DA to levels that were greater than
those achieved by each drug alone (Anneken et al. 2015). As noted above, in Chapter
3, we present our data which demonstrates enhanced dopaminergic activity with coadministration of MDPV, mephedrone, and methylone; thus we hypothesized that the
combination of these cathinones may promote damage to DA nerve endings. Therefore,
in Chapter 4 of this dissertation, we present data from studies aimed to determine if
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chronic co-synthetic cathinone exposure produced significant effects on dopamine
toxicity. This was accomplished using HPLC and immunoblot assays to assess the
levels of DA, TH, DAT, and GFAP in mesolimbic and nigrostriatal brain tissue, and
immunostaining for stereological analysis of DA neurons in the SNpc of mice chronically
treated with the cathinone cocktail. We hypothesized that pharmacological interactions
between MDPV, mephedrone, and methylone following repeated co-exposure would
significantly alter the toxic properties of these drugs in dopaminergic brain regions.
Results from this study showed a unique combined effect that was described as a
‘functional lesion,’ whereby repeated co-synthetic cathinone exposure downregulated
DA, TH and DAT and other key players of the dopaminergic synapse without inducing
blatant reductions in neuronal numbers.
Taken together, these studies have shown that the composition of bath salts
mixtures significantly influences the dopaminergic and toxic effects of these drugs.
These interactions may contribute to the deleterious effects reported by users. Thus, a
deepened knowledge of possible pharmacological interactions resulting from bath salts
abuse will provide a platform for improved overdose and addiction treatment regimens.
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Abstract
A rapid, sensitive, and reproducible assay is described for the quantitative determination
of the monoamine neurotransmitters dopamine, norepinephrine, and serotonin, their
metabolites, and the internal standard 3,4- dihydroxybenzlyamine hydro-bromide
(DHBA) in mouse brain homogenate using high performance liquid chromatography
with electrochemical detection. The method was validated in the following brain areas:
frontal cortex, striatum, nucleus accumbens, hippocampus, substantia nigra pars
compacta, and ventral tegmental area. Biogenic amines and relevant metabolites were
extracted from discrete brain regions using a simple protein precipitation procedure, and
the chromatography was achieved using a C18 column. The method was accurate over
the linear range of 0.300 – 30 ng/mL (r = 0.999) for dopamine and 0.300 – 15 ng/mL (r =
0.999) for norepinephrine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5hydroxyindolacetic acid, with detection limits of approximately 0.125 ng/mL (5 pg on
column) for each of these analytes. Accuracy and linearity for serotonin was observed
throughout the concentration range of 0.625 – 30 ng/mL (r= 0.998) with an analytical
detection limit of approximately 0.300 ng/mL (12 pg on column). Relative recoveries for
all analytes were approximately ≥ 90% and the analytical run time was less than 10 min.
The described method utilized minimal sample preparation procedures and was
optimized to provide the sensitivity limits required for simultaneous monoamine and
metabolite analysis in small, discrete brain tissue samples.
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1. Introduction
Biogenic amines (e.g. dopamine, norepinephrine, and serotonin (5hydroxytryptamine)) serve as major neurotransmitters in the central nervous system
(CNS) and function to mediate various neurophysiological processes, including
motivation, reward/ addiction, movement, attention, cognition, wakefulness, mood,
hunger, temperature regulation, and hormone release (Adinoff, 2004; Carlsson, 1987;
Commissiong, 1985; Cox, 1977; Jouvet, 1972; Leibowitz, 1986; Vitale & Chiocchio,
1993). Disruption of dopamine (DA), norepinephrine (NE), and serotonin (5-HT)
homeostasis is associated with many neuropsychiatric disorders including attention
deficit hyperactivity disorder (ADHD), schizophrenia, anxiety, depression, and
Parkinson’s disease (Delgado, 2000; Huot, Fox, & Brotchie, 2015; Rubia, 2002). Thus,
given the multitude of physiological processes effectuated by these neurotransmitters
and the various neurological conditions associated with their dysregulation, a large
number of pharmacological agents influence the synthesis, storage, release, uptake,
and metabolism of biogenic amines. While DA, NE, and 5-HT play essential roles as
signaling molecules, each regulating a distinct set of CNS functions, they all share the
same major mechanism of inactivation. Of note, all of the monoaminergic
neurotransmitters are regulated in a similar manner, as they are stored in vesicles via
the vesicular monoamine transporter (VMAT), released from synaptic vesicles into the
synaptic cleft, and their action is primarily terminated via reuptake into the presynaptic
neuron. Each monoamine has a specific transporter that allows for its reuptake; for DA,
it is the dopamine transporter (DAT), for NE, the norepinephrine transporter (NET), and
for 5-HT, the serotonin transporter (SERT); however, given structural similarities of
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these transporters, many pharmacological agents that target one of these transporters
have at least some affinity for the other transporters. Additionally, all of the biogenic
amines (DA, NE, and 5-HT) are metabolized by the monoamine oxidase enzyme, and
the catecholamines (DA and NE) are metabolized by catechol-O-methyl transferase
(COMT). Given the large number of pharmaceutical agents and drugs of abuse that
affect monoaminergic systems and their tendency to affect more than one of the
monoamines, there is a need for accurate methods that allow for fast, sensitive, and
simultaneous determination of monoamines and their respective metabolite
concentrations within specific brain regions known to send or receive monoaminergic
input.
Numerous analytical methods employing high performance liquid
chromatography (HPLC) coupled to a variety of detectors including ultra-violet (UV),
fluorescence, electrochemical (ECD), and mass spectrometry (MS), have been
developed to determine monoamine neurotransmitters and relevant metabolite
concentrations in biological samples. HPLC-ECD remains the most commonly used
system for these analyses due to its higher sensitivity compared to other detection
methods (Tsunoda, 2006). Although fast (< 9 min), some previously developed HPLCECD assays utilized for the detection and quantification of DA, NE, 5-HT, and their
metabolites in brain tissue are restricted by their limited sensitivity in this matrix; the
reported lower limits of quantification (LLOQ) for all analytes of interest are insufficient
for analysis of monoamines and their metabolites in discrete brain regions, in particular
within two major dopaminergic nuclei, the substantia nigra pars compacta (SNpc) and
ventral tegmental area (VTA) (Bicker, Fortuna, Alves, & Falcão, 2013; Farthing,
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Halquist, & Sweet, 2015; Parrot, Neuzeret, & Denoroy, 2011). A recent HPLC-ECD
methodology has reported quantification limits adequate for discrete brain region
analysis of DA, DOPAC, and 5-HIAA levels, however, determination of DA turnover
([DOPAC+HVA]/[DA]) within the SNpc and VTA regions would be problematic given the
reported calibration range and LLOQ for HVA (approx. 2.8 ng/mL after 5 µL sample
volume injection) (A. T. Nguyen, Aerts, Van Dam, & De Deyn, 2010). Moreover,
methods which report very sensitive limits of detection (fmol-pmol range) are often
found accompanied by the use of damaging high electrode potentials (> 700 mV) (Bidel
et al., 2016; Parrot et al., 2011; Vaarmann, Kask, & Mäeorg, 2002), the inability to
measure all monoamines and metabolites simultaneously (Heidbreder et al., 2001;
Hubbard et al., 2010), or long analytical run times (> 25 min) (Kumarathasan & Vincent,
2003; A. T. Nguyen et al., 2010; Unceta et al., 2001; Van Dam, Vermeiren, Aerts, & De
Deyn, 2014). Shorter length columns and ultra-high pressure liquid chromatography
(UHPLC) systems are commonly employed to decrease analysis time (Farthing et al.,
2015; Parrot et al., 2011; Reinhoud, Brouwer, van Heerwaarden, & Korte-Bouws, 2013),
however it has been reported that chromatographic efficiency in complex matrices,
particularly during isocratic elution using electrochemical detection, is often reduced as
column length decreases (Bicker et al., 2013; Mutton, 1998; D. T. Nguyen, Guillarme,
Rudaz, & Veuthey, 2006). Moreover, while HPLC –ECD methods allowing for rapid,
simultaneous, and sensitive detection of monoamine and metabolites have been
developed and validated for use in brain dialysates using classical HPLC (Duine, Floch,
Cann-Moisan, Mialon, & Caroff, 1998; Ferry, Gifu, Sandu, Denoroy, & Parrot, 2014;
Reinhoud et al., 2013; Sarre et al., 1992), high background noise due to matrix effects
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and loss of resolution is often observed when applied to brain tissue samples. Thus,
very few methods exist for the rapid and sensitive measurement of monoamine and
metabolites within distinct brain regions. Of these previously developed HPLC-ECD
methodologies, measurements were achieved in larger brain regions, including the
frontal cortex (FCtx), hippocampus (HIP), striatum (STR), and nucleus accumbens
(NAc) but were not assessed in smaller regions, such as the dopaminergic SNpc and
VTA, and LLOQs (S/N ratio ≥ 10) were not reported for these assays. In addition, these
methodologies require ultrafiltration of prepared samples prior to analysis and are thus
susceptible to analyte recovery issues (Bidel et al., 2016; Donzanti & Yamamoto, 1988;
Saito, Murai, Abe, Masuda, & Itoh, 1992).
Therefore, to address the stated limitations, this article reports the development
of a simple and reproducible HPLC-ECD assay for rapid, sensitive, and simultaneous
determination of DA and its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and
homovanillic acid (HVA), 5-HT and its metabolite 5-hydroxyindolacetic acid (5-HIAA),
and NE concentrations in the following mouse brain regions: FCtx, HIP, STR, NAc,
SNpc, and VTA. The proposed methodology has several advantages over earlier
methods including a simple sample preparation procedure that does not require
ultrafiltration of prepared extracts and highly sensitive limits of detection for all six
endogenous compounds that were achieved within an analytical run time of about 9 min
without the use of a UHPLC system.
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2. Experimental
2.1 Chemicals and Reagents
Analytical grade DA, DOPAC, HVA, NE, 5-HIAA, and the internal standard, 3,4dihydroxybenzlyamine hydro-bromide (DHBA) were purchased from Sigma-Aldrich (St.
Louis, MO, USA). For preparation of the mobile phase, certified ACS reagent grade
sodium acetate, citric acid (anhydrous), ethylenediamine tetraacetic acid, disodium salt
(EDTA), glacial acetic acid, and HPLC grade acetonitrile, methanol and polished water
were purchased from Thermo Fisher Scientific (Fair Lawn, NJ, USA). The ion pairing
agent, sodium octyl sulfate (SOS), was purchased from Acros organics (Geel, Belgium)
while 2.0 N perchloric acid was purchased from RICCA chemical (Arlington, TX, USA).
2.2 Apparatus and Operating Conditions
The chromatography was achieved using C18 MD- 150 mm x 3.2 mm, 3 µm column
(Thermo Fisher Scientific). The mobile phase, which consisted of 100 mM sodium
acetate, 20 mM citric acid, 0.38 mM SOS, 0.15 mM EDTA dissolved in 950 mL polished
water and 50 mL acetonitrile, was adjusted to pH 3.3 using glacial acetic acid and
filtered through a 0.22 µm filter (Supelco, Bellefonte, PA, USA). Mobile phase was
delivered to the HPLC system at a flow rate of 0.6 mL/min using an ESA Model 584
pump (ESA Laboratories, Inc., Chelmsford, MA, USA) and prominence degasser (model
DGU-20A5). Electrochemical detection was achieved using a Coulochem® III detector
(ESA Laboratories, Inc.) equipped with 5100A dual electrode. Working potentials of 220 mV and +375 mV were set E1 and E2, respectively. Prepared samples were
injected into the system in 40 µL aliquots using an ESA model 542 autosampler and all
58

analytes were collected in E2 in isocratic elution mode. Data were collected on-line and
exported to an Agilent EZChrome Elite software system (Santa Clara, CA, USA) for
peak area integration and analysis.
2.3 Tissue Collection and Extraction Procedure
Brain tissue used for method validation was obtained from 54 day-old male SwissWebster mice. Mice were sacrificed via decapitation and brains were collected and
placed in ice cold saline for five minutes. After cooling, microdissections were performed
using a mouse brain matrix (30 g Coronal, ASI Instruments, Warren, MI, USA). Brain
sections containing the FCtx, NAc, STR, HIP, and SNpc were collected, halved, and
corresponding brain regions were dissected and weighed from both left and right
halves. The VTA was also collected and weighed from relevant brain slices. Extraction
of monoamines and respective metabolites was performed via optimization of a
previously described protein precipitation method (Wei et al., 2014). Brain tissue
samples were homogenized on ice in five-fold excess volume of methanol for FCtx,
NAc, STR, and HIP regions [volume of MeOH added (µL) = brain weight (mg) x 5], 20
µL methanol for SNpc and VTA samples, and homogenates were centrifuged in 4 °C at
14,000 X g for 20 mins. After, either 40 µl (FCtx, NAc, STR, and HIP) or 10 µl of the
supernatants (SNpc and VTA) were transferred to 1.7 mL microcentrifuge tubes
containing 10 µl of internal standard solution (DHBA, 500 ng/mL prepared in methanol)
and 10 µl polished water. Samples were then vortexed for five minutes and centrifuged
at 3,000 X g for 10 minutes. Supernatants were quantitatively transferred to fresh 5 ml
glass vials and evaporated to dryness under nitrogen gas at room temperature for
approximately 15-20 minutes. Dried samples were reconstituted in 1000 µl (NAc, STR,
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and HIP) or 500 µl (FCtx, SNpc and VTA) of 0.2 N perchloric acid, sonicated for 20
minutes, and stored at -70°C.
2.4 Standard Solutions and Calibration
Standard stock solutions (1.000 mg/mL) of DA, DOPAC, HVA, NE, 5-HT, 5-HIAA, and
the internal standard (IS) DHBA were prepared separately by dissolving the appropriate
amount of the chemical reference in methanol and stored at -70 °C. On the day of
analysis, standard stock solutions were diluted with methanol to achieve a final
concentration of 1.000 µg/mL for each analyte. Working standard solutions were freshly
prepared by further diluting the 1.000 µg/mL stock solutions of DA DOPAC, HVA, NE, 5HT and 5-HIAA with 0.2 N perchloric acid to obtain final concentrations of 0.300, 0.625,
1.250, 2.500, 5.000, 10.000, 15.000, and 30.000 ng/mL for all analytes. DHBA was
spiked into each working standard solution to achieve a final concentration of 5.000
ng/mL (NAc, STR, and HIP calibrations) or 10.000 ng/mL (FCtx, SNpc, and VTA
calibrations), to compensate for variability associated with analyte extraction and
sample injection. For quantitative analyses, standard curves were generated for each
analyte by plotting the peak area ratio (analyte peak area / DHBA (IS) peak area)
versus concentration. The least-squares linear regression method was utilized to
calculate regression equations.
2.5 Linearity, Limit of Detection, and Limit of Quantification
Linearity and analytical limits of the method were evaluated over a wide range of
concentrations. Using individual stock solutions, calibration solutions containing DA,
DOPAC, HVA, NE, 5-HT, and 5-HIAA were prepared in 0.2 N perchloric acid at 10
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concentration levels (range 0.125 ng/mL to 40 ng/mL). Calibration curves were
generated via the internal standardization method and regression equations were
calculated using the least-squares linear regression method. The limit of detection
(LOD) was determined as the analyte concentration which gave a peak area
corresponding to a signal-to-noise (s/n) ratio of 3, while the lower limit of quantification
(LLOQ) was calculated as the analyte concentration that provided a peak area with an
s/n ratio of 10.
2.6 Precision, Accuracy, and Recovery
Instrumental precision (percentage of the relative standard deviation, % RSD) of the
HPLC-ECD system was determined in both nonmatrix (standard solutions in 0.2 N
perchloric acid) and matrix (brain tissue samples) conditions. Accuracy (error
percentage of the determined concentration relative to the nominal concentration, %
Error) of the method was calculated from the analysis of tissue samples fortified with
known quantities of standard. In non-matrix conditions, intra- and Inter- day repeatability
was assessed over three days at the following calibration points: 0.300, 0.625, 1.250,
2.500, 5.000, 10.000, 15.000, and 30.000 ng/mL, using four replicates per concentration
per day (n=12 at each concentration level, see Table 2.2). For method validation in
matrix conditions, brain tissue homogenates were divided into two aliquots. The first
was treated as a ‘blank’ while the second was spiked with a lower (0.800 ng/mL),
medium (2.000 ng/mL and 5.000 ng/mL) and higher (10.000 ng/mL) concentration of
DA, DOPAC HVA, NE, 5-HT, and 5-HIAA prior to extraction. The blank aliquot was
subtracted from spiked samples to normalize for endogenous levels. Intra- and Interday precision and accuracy were assessed in brain matrix over three days at each
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concentration level, using three replicates per concentration per day (n=9 at each
concentration level, see Table 2.3). For both nonmatrix and matrix analyses, five point
internal standard calibration curves were generated for DA, DOPAC, HVA, NE, 5-HT, 5HIAA on the day of analysis. Peak area ratios were utilized for computations and
analyte concentrations were calculated using interpolation of their respective standard
curves. Precision was calculated at each calibration level as %RSD= [(Apa / SD) x 100],
where Apa represents the average peak area ratio measured by the HPLC system and
SD represents the standard deviation. Accuracy was calculated at each calibration
level as % Error = [(|Ca – Cn| / Cn) x 100], where Ca = average concentration of the
analyte as determined by the HPLC-ECD system and Cn= nominal concentration. For
matrix conditions, Apa and Ca values were determined by subtracting analyte peak area
ratios and concentration values measured in ‘blank’ homogenate samples from those
measured in their respective spiked homogenate samples.
3. Results and Discussion
3.1 Method Development
The major analytical difficulty was to determine chromatographic conditions
which provided the desired sensitivity to simultaneously detect monoamines and their
respective metabolites within small, discrete brain tissue samples. The complex matrix
and varied chemistry between the monoamines and their respective metabolites also
contributed to the challenge of optimizing chromatographic conditions. Many HPLCECD methods utilized for monoamine and metabolite analysis in brain tissue report
LLOQs of 5 ng/mL and higher (Farthing et al., 2015; Karimi, Carl, Loftin, & Perlmutter,
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2006), however a more sensitive range is required for accurate analysis in smaller brain
regions such as the SNpc and VTA (0.2 – 1.5 mg tissue weights). Initially, the
commercially available MD-TM mobile phase (Thermo Fisher) was utilized; however,
sensitivity for discrete tissue analysis was insufficient. The final mobile phase
composition was optimized from a method used for the quantitative measurement of
monoamines and corresponding metabolites in rat brain dialysates (Duine et al., 1998).
Sufficient separation of basic and acidic analytes was achieved by modifying both the
pH (3.0-3.6) and the concentration the ion-pairing agent, SOS (0.33-0.45 mM). These
optimization parameters have also been considered in previous analytical HPLC
methodologies to improve both separation and sensitivity of analytes (Brodnik & Jaskiw,
2015; A. T. Nguyen et al., 2010). Increasing the pH decreased retention times of the
acid metabolites; however, this resulted in an overlap of DA and 5-HIAA retention times.
Moreover, increasing SOS concentration increased retention times for monoamines and
also resulted in DA and 5-HIAA peak overlap, while lower SOS concentrations
decreased the retention time of biogenic amines and resulted in DA and DHBA overlap.
Ultimately, the best separation of all analytes was achieved at pH 3.3 and an SOS
concentration of 0.38 mM (Fig. 1A). Utilization of a 3.2 mm I.D., 3 µm particle containing
column as compared to conventional HPLC methods (4.6 mm I.D., 5 µm), allowed
chromatographic separation and quantification of all analytes to occur more rapidly,
resulting in an analytical run time of less than 10 min while also maintaining maximum
system pressure below 170 bar.
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Fig. 2.1. Representative chromatograms showing separation of biogenic amines (NE,
DA, and 5-HT), their respective metabolites (DOPAC, HVA, and 5-HIAA), and the
internal standard DHBA in standard solution at a concentration of 2.5 ng/mL (A) and in
brain homogenate (B).
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3.2 Linearity and Limits of Detection and Quantification
Data for linearity assays is summarized in Table 2.1. The calibration curve was linear for
DA and 5-HT throughout the concentration range of 0.300 – 30.000 ng/mL and 0.625 30.000 ng/mL, respectively, with a mean correlation coefficient of ≥ 0.999 (normal linear
regression, n=10 runs). The calibration curve ranging from 0.300 – 15.000 ng/mL was
linear for NE, DOPAC, HVA, and 5-HIAA (mean correlation coefficient of ≥ 0.998). The
analytical limits of detection and quantification for DA, DOPAC, HVA, 5-HIAA, and NE
were approximately 0.125 ng/mL (5 pg on column) and 0.300 ng/mL (12 pg on column),
respectively. While LOD and LLOQ values for 5-HT were approximately 0.300 ng/mL
(12 pg on column) and 0.625 ng/mL (25 pg on column), respectively. The stated LOD
and LLOQ values were suitable for the quantitative determination of endogenous
monoamine and metabolite levels in the VTA and in halved microdissections of the
FCtx, STR, NAc, HIP, and SNpc (Fig. 2.2, A-F).
Table 2.1. Linearity results of the HPLC-ECD method for the quantification of
monoamines (DA, NE, 5-HT) and various metabolites (DOPAC, HVA, 5-HIAA) in
standard solution
Calibration
range
(ng/mL)
Correlation
coefficient
(r2)
Limit of detection
(ng/mL)
Limit of
quantification
(ng/mL)

DA

DOPAC

HVA

NE

5-HT

5-HIAA

0.300 –
30.000

0.300 –
15.000

0.300 –
15.000

0.300 –
15.000

0.625 –
30.000

0.300 –
15.000

0.999

0.998

0.999

0.999

0.998

0.998

0.125

0.125

0.125

0.125

0.300

0.125

0.300

0.300

0.300

0.300

0.625

0.300
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Fig. 2.2. Representative chromatograms demonstrating detection and separation of DA,
DOPAC, HVA, NE, 5-HT, and 5-HIAA in the following brain regions (A) Frontal cortex;
(B) Hippocampus; (C) Striatum; (D) Nucleus accumbens; (E) Substantia nigra pars
compacta; (F) Ventral tegmental area.
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3.3 Accuracy, Precision, and Recovery
Accuracy and precision of the assay were within the Food and Drug
Administration’s (FDA) requirements for bioanalytical method validation. Combined
inter- and intra-day precision for DA, DOPAC, HVA, NE, 5-HIAA, and 5-HT in nonmatrix conditions was within 12% RSD at each calibration point. These data are
summarized in Table 2.2. Combined intra- and inter- day precision and accuracy for
brain matrix conditions were < 12% RSD and < 10% error for all analytes, respectively
(Table 2.3). Thus, the method demonstrated sufficient precision and accuracy for
monoamines and respective metabolites using the aforementioned chromatographic
conditions and sample preparation procedure. Moreover, the described method
achieved chromatographic selectivity without interference from other endogenous brain
matrix constituents at the retention times of each analyte of interest (Fig. 2.1B).
Table 2.2 Inter- day accuracy (% Error) and precision (%RSD) of the HPLC- ECD assay
for quantification of DA, DOPAC, HVA, NE, 5-HT, and 5-HIAA in 0.2 N perchloric acid
(n= 12 for each concentration)
DA
[C]
ng/ml
0.300
0.625
1.250
2.500
5.000
10.000
15.000
30.000

DOPAC

Mean

% RSD

Mean

% RSD

0.330
0.559
1.220
2.496
5.018
9.364
14.734
29.694

5.925
11.681
1.739
1.117
1.224
6.114
3.916
2.333

0.329
0.736
1.232
2.333
4.884
9.562
14.942
-

8.575
6.665
4.064
2.407
0.940
3.639
2.778
-

NE
[C]
ng/ml
0.300
0.625
1.250

5-HT

HVA
Mean

% RSD

0.291
4.214
0.573
9.839
1.192
2.219
2.432
1.588
4.872
1.093
9.335
6.327
14.749
3.985
5-HIAA

Mean

% RSD

Mean

% RSD

Mean

% RSD

0.288
0.594
1.265

5.345
12.305
4.056

0.661
1.163

10.643
4.075

0.325
0.583
1.226

4.310
13.344
3.072
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2.500
5.000
10.000
15.000
30.000

2.543
5.048
9.762
15.011
-

2.336
1.569
11.567
4.065
-

2.514
5.068
8.823
14.321
30.078

1.735
1.565
7.155
4.221
2.153

2.603
5.236
10.917
17.017
-

2.274
1.814
9.139
5.300
-

Table 2.3: Inter-day and accuracy and precision of the HPLC-ECD assay for
quantification of all analytes in brain tissue homogenate (n= 9 for each concentration).

DA
Spiked
[C]
(ng/mL)
0.80
2.00
5.00
10.00

Mean
[C]
found
0.83
1.96
4.84
9.55

Spiked
[C]
(ng/mL)
0.80
2.00
5.00
10.00

Mean
[C]
found
0.88
1.92
5.36
9.68

DOPAC

%Error %RSD
4.53
4.11
3.22
4.51
NE

2.24
5.68
3.10
4.37

%Error %RSD
10.27
8.99
7.12
4.81

2.41
8.54
6.28
4.88

Mean
[C]
found
0.82
2.02
4.90
10.00
Mean
[C]
found
0.78
2.19
5.28
10.45

HVA

%Error %RSD
6.38
2.84
7.52
0.53
5-HT

3.16
11.87
4.94
2.07

%Error %RSD
5.62
9.68
8.58
4.60

6.02
3.68
8.65
4.63

Mean
[C]
found
0.78
2.10
5.19
10.16
Mean
[C]
found
0.86
2.13
5.52
10.73

%Error %RSD
4.26
4.76
9.62
9.10
5-HIAA

1.41
5.99
4.39
4.18

%Error %RSD
7.06
6.31
10.38
7.27

3.49
6.53
4.51
4.34

3.4 Measurement of Monoamine and Metabolites in Discrete Brain Tissue Samples
The relative concentration levels of monoamines and metabolites measured in the FCtx,
STR, NAC, HIP, SNpc, and VTA brain regions are presented in Table 2.4. These values
accurately represent the degree of monoaminergic input within each brain region and
are in agreement with the values previously reported for mice brain tissue (Donzanti &
Yamamoto, 1988; Saito et al., 1992). Specifically, within the brain regions comprising
the dopaminergic brain reward (NAc and VTA) and motor control (STR and SNpc)
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pathways, tissue levels of DA and respective metabolites were determined to be
significantly higher than those of the FCtx and HIP; with the major DA projection sites,
NAc and STR, containing the highest levels of DA (ng/mg) as compared to all other
brain regions analyzed by this method. Moreover, while the FCtx and HIP brain regions
are described to be diffusely innervated by DA neurons, neuronal input from
noradrenergic (NE) and serotonergic systems is more abundant. Thus, the present data
showing greater concentrations of NE and 5-HT as compared to DA within in these
brain areas is expected.
Table 2.4. Relative concentration levels of biogenic amines and metabolites in discrete
brain regions
Analyte concentration levels (ng/mg wet tissue)
Brain
Region
FCtx (Fig. 2A)
HIP (Fig. 2B)
NAc (Fig. 2C)
STR (Fig. 2D)
SNpc (Fig. 2E)
VTA (Fig. 2F)

DA
0.18
0.19
3.33
3.55
1.56
1.49

DOPAC

HVA

0.24
0.15
0.54
0.71
1.09
0.70

0.11
0.09
0.47
0.53
0.51
0.44

NE
0.51
0.43
0.45
0.32
1.61
2.37

5-HT
0.26
0.23
0.18
0.22

5-HIAA
0.27
0.25
0.31
0.33

4. Conclusions
DA, NE, and 5-HT are widely distributed throughout the CNS, serving as
neurotransmitters and regulating a number of physiological and behavioral processes
including cognitive and mnemonic processes (FCtx, HIP), reward and addiction (VTA,
NAc), and movement (SNpc, STR). As dysregulation of these neurotransmitter systems
is associated with numerous neuropsychiatric disorders, a growing number of
pharmacological agents are utilized to either increase or reduce monoamine levels. In
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order to assess the effectiveness of such agents, a sensitive analytical assay allowing
for simultaneous detection of monoamine neurotransmitters and relevant metabolites
within these discrete brain regions is required. This paper reports a rapid, sensitive, and
reproducible HPLC-ECD method for the separation and quantification of DA, DOPAC,
HVA, NE, 5-HT, and 5-HIAA in mouse brain tissue homogenate using DHBA as the
internal standard. The proposed analytical method utilizes a simple sample preparation
procedure that does not require the ultrafiltration of prepared tissue extracts and results
in recoveries ≥ 90% for all analytes. Optimization of mobile phase pH and SOS
concentration resulted in effective separation of monoamines and respective
metabolites on a C18 150 mm, 3 µm column, within an analytical run time of
approximately 9 min. Therefore, the present method circumvents the need for
dedicated UHPLC systems for rapid analysis (< 10 min) of brain tissue monoamines
and relevant metabolites and is desirable for high-throughput approaches. Moreover,
given the highly sensitive quantification limits reported for all analytes (0.300 - 0.625
ng/mL), this HPLC-ECD assay is suitable for quantitative analysis of these endogenous
compounds within multiple areas of the brain, including the small nuclei of the SNpc and
VTA (0.2 – 1.5 mg tissue weights), in mice. Thus, the proposed analytical method
provides a fast, sensitive, and reliable means by which to evaluate the pre-clinical
effects of pharmaceutical agents on monoaminergic tone within distinct brain regions
and pathways.
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Introduction
The synthetic cathinones include a class of designer β-ketone amphetamine
compounds that are chemically related to the plant-derived stimulant, cathinone. The
three most commonly abused synthetic cathinones, MDPV, 4-methylmethcathinone
(mephedrone), and 3, 4-methylenedioxymethcathinone (methylone), received
international popularity as psychoactive components in ‘bath salts,’ a marketing term
used in conjunction with labels stating “not for human consumption” as a way to
circumvent existing drug laws and allow for their legal distribution (DEA, 2014; Spiller et
al., 2011). In recent years, the extensive abuse of bath salts as cheap and ‘legal’
alternatives to illicit psychostimulant compounds precipitated an alarming rise in the
number of individuals requiring emergency medical treatment after synthetic cathinone
intoxication (CDC, 2011; Deluca et al., 2012; SAMHSA) and led to the DEA
classification of bath salt constituents, MDPV, mephedrone, and methylone as schedule
I controlled substances in 2011(DEA, 2011). However, synthetic cathinone abuse
appears unabated (Mounteney et al., 2016; Palamar et al., 2015) due in large part to the
internet serving as clandestine marketplace for these drugs (Karila et al., 2015; Power,
2014). The growing prevalence of MDPV, mephedrone, and methylone has prompted a
number of preclinical investigations on the effects of these drugs on the central nervous
system (CNS).
Pharmacokinetic studies have shown these synthetic cathinones readily cross
the blood brain barrier and accumulate in rodent brain tissue, reaching peak
concentrations within 15-30 min (Novellas et al., 2015; Peters et al., 2016; Štefková et
al., 2017; Šíchová et al., 2017). In vitro transporter and electrophysiology assays have
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revealed the individual pharmacological mechanisms of MDPV, mephedrone, and
methylone. MDPV functions as a selective inhibitor of dopamine transporter (DAT)
activity by blocking the reuptake of dopamine, similar to cocaine but more potent
(Baumann et al., 2013; Cameron et al., 2013a). In contrast, mephedrone and
methylone behave as non-selective substrates for monoamine transporters, thereby
inducing transporter-mediated release of dopamine (DA), norepinephrine (NE), and
serotonin (5-HT), similar to the actions of 3,4-methylenedioxymethamphetamine
(MDMA, ecstasy) and other amphetamines (Baumann et al., 2012; Solis, 2016). Despite
pharmacological and DAT selectivity differences, all three synthetic cathinones were
found to precipitate rapid and marked elevations in extracellular DA (Baumann et al.,
2012; Baumann et al., 2013; Shortall et al., 2013) and increase locomotor activity in
rodents (Gregg and Rawls, 2014; Marusich et al., 2012). Moreover, the ability of MDPV
and mephedrone to progressively increase locomotor activity and stereotypy, a
phenomenon termed behavioral sensitization, has been demonstrated in several studies
(Fantegrossi et al., 2013; Gregg et al., 2013a; Marusich et al., 2012).
While there is now a sizable body of evidence on the individual effects of MDPV,
mephedrone, and methylone, forensic analysis has shown that bath salts formulations
often contain various concoctions of these synthetic cathinones, with both binary and
ternary mixtures of MDPV, mephedrone, and methylone detected in many of the most
frequently abused bath salt ‘brands ‘ (Spiller et al., 2011; Warrick et al., 2013) .
Therefore, it is important to also evaluate the neurochemical and behavioral effects of
these drugs when administered in various combinations to more accurately model bath
salts abuse.
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Additive, or synergistic, interactions are often more profound when drug cocktails
are composed of compounds which individually produce qualitatively similar effects via
distinct pharmacological mechanisms (Tallarida, 2011). Therefore, because both nonsubstrate (MDPV) and substrate synthetic cathinones (mephedrone and methylone)
exert their psychostimulant effects by increasing synaptic DA levels, the dichotomy of
their interaction with the DAT suggests an avenue for enhanced dopaminergic effects
when these drugs are co-abused. While a few studies have analyzed the reinforcing
(Gannon et al., 2018) and stimulant (Berquist et al., 2016) properties of different binary
mixtures of the synthetic cathinones, the current study represents the first known
attempt to characterize the effects of ternary mixtures of MDPV, mephedrone, and
methylone on tissue DA levels and locomotor activation in comparison to each
compound alone. The results presented here suggest that the dopaminergic effects of
MDPV, mephedrone, and methylone are significantly enhanced when they are coadministered as a cocktail.
Materials and Methods
Animals
The experiments utilized adolescent male Swiss-Webster mice (Harlan Inc.,
Indianapolis, IN) weighing 20-30 g. Male adolescent mice were chosen for this study as
drug survey reports suggest the main abusers of synthetic cathinones are young male
adults (Karila et al., 2015; Vardakou et al., 2011). The experimental protocol was
approved by the ETSU University Committee on Animal Care (UCAC) and followed the
National Institute of Health Guidelines for the Care and Use of Laboratory Animals. All
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drugs were dissolved in saline and injected at a volume of 0.01 mL/g body weight.
Control animals were injected with equal volumes of sterile saline.
Drugs and Reagents
Analytical grade MDPV ((±) 3, 4-methylenedioxypyrovalerone HCl), mephedrone ((±) 4methylmethcathinone HCl), and methylone ((±)3, 4-methylenedioxymethcathinone HCl)
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Certified reference standard
grade DA, 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 3,4dihydroxybenzlyamine hydro-bromide (DHBA) were also purchased from Sigma-Aldrich.
The ion pairing agent, sodium octyl sulfate (SOS), was purchased from Acros organics
(Geel, Belgium) and 2.0 N perchloric acid was purchased from RICCA chemical
(Arlington, TX, USA). All other certified ACS chemicals and reagents used in this study
were purchased from Thermo Fisher Scientific (Fair Lawn, NJ, USA).
Determination of Monoamine Levels
Animal dosing. Mice were separated into the following cohorts (n= 4-6 per
group): 1) saline 2) 1 mg kg-1 MDPV 3) 10 mg kg-1 MDPV, 4) 1 mg kg-1 mephedrone, 5)
10 mg kg-1 mephedrone, 6) 1 mg kg-1 methylone, 7) 10 mg kg-1 methylone, 8) 1 mg kg-1
cathinone cocktail, 9) 3.33 mg kg-1 cathinone cocktail, 10) 10 mg kg-1 cathinone
cocktail, and appropriately dosed with a single intraperitoneal (IP) injection of saline or
corresponding drug. All doses were chosen in accordance to DEA statistical reports
indicating the average range of bath salt abuse per session varies widely from 25 mg- 5
g (DEA, 2011). As insufflation is the predominate modality utilized by bath salt abusers,
IP injections were chosen for this study based on their analogous pharmacokinetic
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profile to snorting (Bradberry, 2002). Fifteen minutes after injection, animals were
deeply anesthetized with isofluorane, sacrificed by decapitiation, and brains were
collected immediately and placed in ice-cold saline for 5 min. This time frame was
chosen based on a previous pharmacokinetic study from our laboratory indicating that
peak brain concentrations of MDPV, mephedrone, and methylone following IP injections
are achieved at 15 minutes (Peters et al., 2016). Brains were sliced in 2 mm sections
using a chilled stainless steel 30 g coronal mouse brain matrix (MSI) and
microdissections of the nucleus accumbens (NAc), striatum (STR), substantia nigra
pars compacta (SNpc), and ventral tegmental area (VTA) were performed in accord to
the mouse brain atlas (Paxinos and Watson). Collected tissue was flash-frozen in liquid
nitrogen and stored at -70°C until further analysis.
HPLC-ECD. DA, DOPAC, and HVA were extracted and quantified from collected
brain tissue using a previously described HPLC-ECD method (Allen et al., 2017).
Briefly, collected tissue samples were thawed, weighed, homogenized in methanol,
spiked with the internal standard 3,4-dihydroxybenzylamine (DHBA), and centrifuged at
13,000 g. Supernatants were collected, dried under nitrogen gas, and reconstituted in
0.2 N perchloric acid. DA, DOPAC, and HVA were separated using a C18 MD- 150mm x
3.2mm, 3µm column (Thermo Fisher Scientific) and detected at a potential of + 375 mV
by a Coulochem® III coulometric detector (ESA Laboratories). The mobile phase, which
consisted of 0.22 µm filtered 100 mM sodium acetate, 20 mM citric acid, 0.38 mM SOS,
0.15 mM EDTA and 5% v/v acetonitrile adjusted to pH 3.3 with glacial acetic acid, was
delivered at 0.6 mL/min by an isocratic pump. Quantification was achieved using the

80

Agilent EZChrome Elite software system (Agilent Technologies). DA turnover was
calculated as [DOPAC+HVA]/[DA].
Locomotor Activity
Animal dosing. Mice were randomly separated into four groups (n=6-8): 1) saline,
2) 10 mg kg-1 MDPV (uptake inhibitor), 3) 10 mg kg-1 mephedrone (substrate), and 4) 10
mg kg-1 MDPV + 10 mg kg-1 mephedrone + 10 mg kg-1 methylone. In order to reduce
animal numbers, only the high dose of each drug was utilized and only the highest
potency substrate drug (mephedrone) was utilized.
Apparatus. Behavioral experiments were carried out using a locomotor arena that
consisted of a square wooden box measuring 40 x 40 cm painted black. AnyMaze
tracking software (ANYmaze, Stoelting Co., Wood Dale, IL) was used to superimpose
grid lines on the locomotor arena and measure locomotor activity. A computer interface
was used to automatically tabulate total distance traveled (m) or stereotypy (counts).
Immobility episodes lasting longer than 3 s were considered as stereotypy.
Procedure. Animals were habituated to the locomotor arena for three consecutive
days before drug dosing. For each habituation, mice were given IP injections of 0.9%
saline 15 min prior to being placed in the locomotor area. Following habituation, mice
were randomly separated into the four treatment groups listed above and
correspondingly dosed in their home cages with drug or saline every other day for 14
days, a total of 7 injections. Animals were placed in the locomotor arena 15 min after
each drug administration and behavior was recorded and tracked for 10 min using
AnyMaze. Locomotor activity was recorded on test days 1 and 7, and testing sessions
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for both habituation and treatment runs were 10 min. This seven-day dosing schedule
is similar to the paradigm used by Berquist et al. (2016), with 48 h drug intervals chosen
in accordance with Watterson et al. (2016).
Statistics
All statistical analyses were performed using GraphPad Prism version 5.0 for Windows
(GraphPad Software, San Diego, CA, USA). Neurochemical data from HPLC-ECD
analysis were evaluated using two-way analysis of variance (drug treatment x dose)
followed by Bonferroni’s post hoc test. For locomotor activity experiments, total
distanced traveled (m) and the number of immobility or stereotypic episoides were
summed over the course of the 10 min testing period on day 1 and day 7 and evaluated
using two-way analysis of variance (drug treatment x testing day) followed by NewmanKeuls post hoc test. The minimum criterion for statistical significance was P < 0.05. The
use of high and low drug doses, drug combinations, and analysis of multiple analytes in
various different brain regions resulted in a very large number of planned comparisons.
Thus, the outcomes from statistical tests for DA, DOPAC, HVA, and DA turnover are
described minimally in Results, and full descriptions of all neurochemical statistical
outcomes are presented in Tables S1-S4.
Results
Individual Effects of MDPV, Mephedrone, and Methylone on Brain Tissue Dopamine
Concentration and Turnover Rate in Acutely Exposed Mice
Mice were acutely treated with MDPV, mephedrone, and methylone at either a
low (1 mg kg-1) or high (10 mg kg-1) dose of each drug alone. Figure 3.1 shows the
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results of these treatments on DA within the mesolimbic and nigrostriatal brain
pathways 15 min post drug exposure. The main effects of dose and drug treatment as
well as their interactions on DA concentration and turnover were statistically significant
(p < 0.05 – p < 0.0001) in each brain region analyzed (Table S1). At the high dose (10
mg kg-1), MDPV and mephedrone produced significant increases in DA over control
values in all brain areas including the DA nuclei of the midbrain (SNpc and VTA) and
their corresponding major projection sites (STR and NAc). Methylone (10 mg kg-1)
caused significant, selective increases in mesolimbic DA (NAc and VTA) in comparison
to controls. Conversely, no change in DA tissue content was observed following acute,
low dose (1 mg kg-1) administration of MDPV, mephedrone, or methylone.
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Figure 3.1 The acute effects of MDPV, mephedrone, and methylone on DA levels in the
NAc (A), STR (B), VTA (C), and SNpc (F). Numerals below each indicate the treatment
dose in mg kg-1. DA levels are reported as % of control. Data are expressed as mean ±
SEM, n = 4-6 mice per treatment group; * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control.
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The effect of each drug on DA metabolite levels (HVA and DOPAC) was also
assessed using HPLC analysis, and results are presented in Table 3.1. Significantly
increased levels of HVA (NAc, STR, SN, and VTA) and decreased levels of DOPAC
(SNpc and VTA) were measured in mice that received a single injection of MDPV at the
high dose (10 mg kg-1). The low dose of MDPV (1 mg kg-1) significantly increased tissue
HVA levels in the SNpc and VTA, but did not cause any significant alterations in
DOPAC levels. At both treatment doses, mephedrone caused a marked increase in
HVA in four brain regions. Methylone also produced region-wide significant increases in
HVA tissue levels at the higher dose, but these effects were not observed at the lower
dose. Both of the substrate cathinones decreased DOPAC (NAc, STR, and SN) levels
following high dose administration, while low dose exposure to neither mephedrone nor
methylone caused significant alterations in DOPAC levels. DA metabolite
concentrations and their summed ratios to DA were used to evaluate the acute effect of
each synthetic cathinone on DA transmitter utilization and metabolism (Fig 3.2);
apparent DA turnover was evaluated in each brain region by calculating the ratio of the
total concentrations of DA metabolites (HVA + DOPAC) to DA. At the high dose, MDPV,
mephedrone, and methylone each produced a marked reduction in DA turnover values
as compared to control in all brain regions analyzed, while at the lower dose, each drug
decreased DA turnover in the VTA only.

84

B

A

STR DA turnover

NAc DA turnover
150

Control
MDPV
mephedrone
methylone

100

**

*

DA turnover
(% control)

DA turnover
(% control)

150

**
50

100

50

0

0
C

1

10

1

10

1

C

10

C

1

10

1

10

1

10

D
VTA DA turnover

SN DA turnover

150

100

**

***

***
50

Control
MDPV
Mephedrone
Methylone

*

**

150

DA turnover
(% control)

DA turnover
(% control)

***

***

***

Control
MDPV
Mephedrone
Methylone

***

Control
MDPV
Mephedrone
Methylone

100

***

50

***

0

0
C

1

10

1

10

1

10

C

1

10

1

10

1

10

Figure 3.2 The acute effects of MDPV, mephedrone, and methylone on DA turnover in
the NAc (A), STR (B), VTA (C), and SNpc (F). Numerals below each indicate the
treatment dose in mg kg-1. DA levels are reported as % of control. DA turnover is
reported as % of control. Data are expressed as mean ± SEM, n = 4-6 mice per
treatment group; * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control.

Table 3.1 DA metabolite levels following individual and combined exposure to MDPV,
mephedrone, and methylone. Data shows the average content (ng/mg wet tissue) of
DOPAC and HVA in the NAc, STR, VTA, and SNpc 15 min post injection of drug or
saline. Data are expressed as mean ± SD, n = 4-6 per group. Significance is
indicated in Table S1-S2.

NAc

STR

Meph
Combo Combo MDPV MDPV Meph
10
Saline 1 mg
3.3 mg 1 mg
10 mg 1 mg
mg
kg-1
kg-1
kg-1
kg-1
kg-1
kg-1
1.0 ±
1.0 ±
0.9 ±
0.8 ±
1.2 ±
0.9 ± 0.6 ±
DOPAC
0.1
0.1
0.1
0.2
0.3
0.3
0.1
0.5 ±
0.7 ±
0.7 ±
0.7 ±
1.1 ±
0.6 ± 0.8 ±
HVA
0.1
0.1
0.1
0.2
0.2
0.1
0.1
0.7 ±
0.6 ±
0.9 ±
0.6 ± 0.8 ±
0.7 ± 0.5 ±
DOPAC
0.1
0.1
0.2
0.1
0.1
0.2
0.1
0.5 ±
0.7 ±
1.0 ±
0.6 ±
1.4 ±
0.8 ± 0.9 ±
HVA
0.1
0.1
0.2
0.1
0.2
0.2
0.1
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Methy
Methy
10
1 mg
mg
kg-1
kg-1
0.7 ± 0.6 ±
0.1
0.1
0.5 ± 0.7 ±
0.1
0.1
0.6 ± 0.5 ±
0.1
0.0
0.6 ± 0.8 ±
0.1
0.2

0.6 ±
0.1
0.3 ±
HVA
0.1
0.6 ±
SNpc DOPAC
0.1
0.2 ±
HVA
0.0

VTA

DOPAC

0.5 ±
0.2
0.7 ±
0.1
0.5 ±
0.1
0.4 ±
0.1

0.3 ±
0.1
0.6 ±
0.1
0.3 ±
0.1
0.3 ±
0.1

0.8 ±
0.2
0.7 ±
0.1
0.6 ±
0.2
0.4 ±
0.1

0.3 ±
0.1
0.5 ±
0.1
0.3 ±
0.1
0.5 ±
0.1

0.6 ±
0.1
0.5 ±
0.1
0.3 ±
0.1
0.3 ±
0.1

0.5 ±
0.1
0.5 ±
0.1
0.2 ±
0.0
0.5 ±
0.1

1.0 ±
0.1
0.5 ±
0.1
0.5 ±
0.1
0.4 ±
0.1

0.7 ±
0.1
0.5 ±
0.2
0.3 ±
0.1
0.3 ±
0.0

Synergistic Effects of Combined Synthetic Cathinone Exposure on Mesolimbic and
Nigrostriatal DA Content
‘Bath salts’ products often contain various mixtures of MDPV, mephedrone,
and/or methylone. Given the fact that pharmacological data presented here (Fig 3.1)
and elsewhere (De Felice et al., 2014) suggest that these drugs individually function to
modulate DA release to an extent; we also evaluated the acute, combined effect of
MDPV, mephedrone, and methylone on brain tissue DA concentration and turnover. For
combined treatment, mice received a single injection of a cathinone cocktail composed
of MDPV, mephedrone, and methylone, each at a dose of 10 mg kg-1 (30 mg kg-1
cathinones in total), 3.3 mg kg-1 (~ 10 mg/kg cathinones in total), or 1 mg kg-1 (3 mg kg-1
cathinone total). The overall effect of each combo dose on regional specific DA levels is
presented in Fig 3.3. The results of combined treatments as compared to those of both
control and dose matched individual cathinone treatment are presented in Fig 3.4 (DA
levels) and Fig 3.5 (DA turnover).
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Figure 3.3 Tissue DA content corresponding to increasing doses of the cathinone
cocktail. Data are expressed as % of control values. Significant increases are observed
from 1 mg kg-1 to 3.3 mg kg-1 in all brain regions, except the VTA. Comparisons and
levels of significance are reported in Tables S3-S4. DA levels appear to plateau
following a single 3.3 mg kg-1 combined cathinone exposure as no significant
differences were observed in any brain area when compared to the 10 mg kg-1 cocktail.

DA was significantly increased in all brain areas following acute exposure to the
cathinone cocktail at all doses (Fig 3.3 and Table S1-S2). The DA response following
co-administration of MDPV, mephedrone, and methylone appears to be due to
synergistic interactions between the drugs as evidenced by two different statistical
comparisons (Fig 3.4). First, while none of the synthetic cathinones significantly affected
tissue DA levels over control values when individually administered at a dose of 1 mg
kg-1, co-administration of 1 mg kg-1 MDPV + 1 mg kg-1 mephedrone + 1 mg kg-1
methylone resulted in DA elevations that were statistically significant across all brain
regions analyzed. Second, mesolimbic and nigrostriatal DA levels were significantly
greater in mice treated with the high dose cathinone cocktail (3.3 mg kg-1 MDPV + 3.3
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mg kg-1 mephedrone + 3.3 mg kg-1 methylone) as compared to mice treated with 10 mg
kg-1 of MDPV, mephedrone, or methylone, individually. Thus, combined 3.3 mg kg-1
doses of the three drugs resulted in increased tissue DA to levels that were significantly
greater than those produced by any of the individual drugs at 10 mg kg-1 doses (Fig
3.4).
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Figure 3.4 The effects of combined exposure to MDPV, mephedrone, and methylone
on DA levels in the NAc (A), STR (B), VTA (C), and SNpc (D) of mice following acute
dosing. Low dose values include 1 mg kg-1 individual and combined drug treatments.
High dose values include 10 mg kg-1 individual drug treatments and 3.3 mg kg-1
cathinone cocktail. Data are expressed as mean % of control ± SEM (n = 4-6 mice per
group); * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control (c) in both the low and high dose
treatment groups, while # = p < 0.05 vs. the corresponding cathinone cocktail.

However, DA metabolites were not as profoundly affected by the cocktail as
compared to the individual drugs (see Table 3.1). DA turnover values for the 1 mg/kg
cathione cocktail were significantly reduced from those of control and the individual low
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dose drug treatments in all brain areas except the VTA. While the 3.3 mg/kg cocktail
significantly reduced DA turnover as compared to control and methylone (10 mg kg-1) in
all brain regions, these reductions were statistically different from MDPV (10 mg kg-1)
individual drug treatment in the NAc only (Fig 3.5).
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Figure 3.5 The effects of combined exposure to MDPV, mephedrone, and methylone
on DA turnover in the NAc (A), STR (B), VTA (C), and SNpc (D) of mice following acute
dosing. Low dose values include 1 mg kg-1 individual and combined drug treatments.
High dose values include 10 mg kg-1 individual drug treatments and 3.3 mg kg-1
cathinone cocktail. Data are expressed as mean % of control ± SEM (n = 4-6 mice per
group); * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control (c) in both the low and high dose
treatment groups, while # = p < 0.05 vs. the corresponding cathinone cocktail.
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Effect of Individual and Combined Synthetic Cathinone Exposure on Locomotor Activity
and Immobility Counts in Mice
The acute (day 1) and subchronic (day 7) effects of MDPV and mephedrone,
individually and in combination with methylone, on locomotor activity are presented in
Fig 3.6. Animals were administered intermittent doses of appropriate drug or saline and
activity testing began 15 min after treatment. Immobility episodes of 3 s or longer were
counted and used as an index of stereotypy, as animals tracked as immobile were
observed to be exhibiting stereotypic behavior (Fig 3.6B). A two-way ANOVA revealed
highly significant main effects of drug treatment and testing day (p < 0.0001). No
significant changes in motor activity were observed in the mephedrone group on either
the first or last day of drug treatment. However, locomotion was significantly decreased
over the course of treatment in both the MDPV and combined cathinone groups, while
the acute effects of these treatments differed. MDPV treatment significantly enhanced
forward locomotion on day 1 (observed as a significant increase in distance traveled)
and had no effect on immobility or stereotypic episoides. In contrast, the combo
treatment significantly reduced motor activity and increased stereotypic counts on day
1. On the final treatment day, both drugs induced hypolocomotion and significantly
increased immobility counts, with motor activity in the combo group significantly less
than that observed on day 1.
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Figure 3.6 Locomotor activity levels (A) and immobility counts (B) in mice repeatedly
administered 10 mg kg-1 doses of MDPV, mephedrone, or the cathinone cocktail
(combo). Animals were placed in the locomotor arena 15 min post-injection and
locomotor activity was measured on day 1 (acute) and day 7 (subchronic) as total
distance traveled or cumulative immobility episodes over a 10 min testing period. Data
are expressed as group means (n = 6-8 per group) ± SEM, * p < 0.05 vs. saline.

Discussion
The primary aim of the present study was to evaluate and compare how major
bath salt constituents MDPV, mephedrone, and methylone acutely influence mesolimbic
and nigrostriatal DA levels and locomotor activity when administered individually and in
combination. Neurochemical and behavioral assays were performed 15 min post
exposure, a time point in which all three compounds are reported to reach peak
concentrations in the mouse brain (Peters et al., 2016). Given that MDPV, mephedrone,
and methylone primarily produce their abuse-related effects by enhancing DA signaling
(Gatch et al., 2013; Karlsson et al., 2014) and that popular bath salt ‘brands’ generally
contain various mixtures of these compounds (Warrick et al., 2013), investigations into
their combined effects on DA neurotransmission and motor activity are clearly
warranted.
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In the present study, we found that all three synthetic cathinones produced
significant, dose-related increases in mesolimbic DA levels, with MDPV and
mephedrone also producing dose-related increases in striatal and nigral DA content.
Moreover, DA elevations detected in the NAc and STR of mice treated with MDPV were
significantly greater than those found in mephedrone and methylone-treated mice,
suggesting that MDPV is more potent than the substrate cathinones at increasing tissue
DA levels in DAT-rich brain regions. These findings are in agreement with several
microdialysis studies reporting rapidly elevated dialysate DA levels following synthetic
cathinone administration, with the greatest increases reported with MDPV (Baumann et
al., 2013; German et al., 2014; Schindler et al., 2016). The overall effect of each drug
treatment on DA metabolism was similar, with all three compounds significantly
reducing DA turnover to values that were comparable between the individual drug
treatment groups.
These effects can be attributed to increased synaptic DA levels and blockade of
intraneuronal DA metabolism. Notably, DA elevations were accompanied by significant
increases in HVA by all three cathinones, while DOPAC was either decreased or
unaltered. Similar effects on DA metabolites have been described in freely moving
rodents acutely treated with the synthetic cathinones at comparable doses (LópezArnau et al., 2018; López-Arnau et al., 2017). Given that the conversion of DA to HVA
involves catechol-O-methyltransferase (COMT), an enzyme that is notably absent from
dopaminergic terminals (Kastner et al., 1994), while the conversion of DA to DOPAC is
mediated by monoamine oxidase (MAO), an enzyme found within presynaptic nerve
terminals (Graves et al., 2017), these data likely reflect the DA reuptake-inhibiting
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actions of the synthetic cathinones. Thus, the blockade of DA re-entry into the
intracellular substrate pool prevents MAO degradation and leads to an increase in the
synaptic pool of DA available for extraneuronal metabolism by COMT in glial cells
(Gulley and Zahniser, 2003). Additionally, tissue levels of HVA appeared to positively
correlate to DA elevations, with MDPV also producing the greatest elevations in HVA in
the neuron terminal regions (NAc and STR). Interestingly, the substrate cathinones
produced significantly greater reductions in accumbal and striatal DOPAC levels when
compared to controls and MDPV. Given the fact that other amphetamine-like
compounds have been shown to inhibit MAO (Sitte and Freissmuth, 2015), these data
may reflect a similar action of mephedrone and methylone.
The combined delivery of the synthetic cathinones resulted in acute elevations in
DA that were significantly greater than those observed with MDPV, mephedrone, or
methylone alone in all collected brain regions. This was observed at all doses of the
cathinone cocktail analyzed (1 mg kg-1, 3.3 mg kg-1, and 10 mg kg-1). As none of the
drugs significantly changed DA over control levels when individually administered at the
1 mg kg-1 dose, the 1 mg kg-1 cathinone cocktail was utilized to determine if any
significantly altered effects are achieved following co-administration of the synthetic
cathinones at doses that were pharmacologically insignificant when individually
administered. As such, we found that DA was significantly increased in all brain regions
of mice treated with the 1 mg kg-1 cocktail as compared to both control and 1 mg kg-1
individual drug treatments. In order to determine if this enhanced response was a result
of synergistic drug interactions or an additive effect due to an increase in total synthetic
cathinone load (e.g. 3 mg kg-1 total cathinones in cocktail vs. 1 mg/kg individual
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synthetic cathinones), we utilized the cocktail composed of 3.3 mg kg-1 MDPV + 3.3 mg
kg-1 mephedrone + 3.3 mg kg-1 methylone (10 mg kg-1 total cathinone exposure) and
directly compared results of this treatment group with those obtained in both control and
10 mg kg-1 individual cathinone groups. From these analyses, we found that 1) the 3.3
mg kg-1 combo treatment significantly increased DA levels over control values and 2)
DA elevations were significantly greater than those achieved by any of the synthetic
cathinones when individually administered at 10 mg kg-1. Thus, a significantly greater
DA response was achieved by the drug combination, despite a 3 fold decrease in the
dose of each individual cathinone, suggesting that this effect is product of drug
synergism and not simply due to addition or increased total cathinone load (Tallarida,
2011). Taken together, these data show that the individual abilities of MDPV,
mephedrone, and methylone, to increase mesolimbic and nigrostriatal DA levels are
enhanced when they are given in conjunction one another. This, enhanced effect may
be attributed to the synergistic pharmacokinetic effect demonstrated by Cameron and
colleagues (2013b), whereby the substrate and DA-releasing activity of mephedrone
and methylone precedes the blocking actions of MDPV, and is supported by studies
demonstrating that mephedrone and binary mixtures of MDPV + mephedrone enhance
the stimulant effect of DAT-blocker cocaine (Berquist et al., 2016).
Given that midbrain dopamine circuits are primarily implicated in the activation
and sensitization of locomotor responses (Uhl et al., 2002), it is interesting to evaluate
these effects in mice treated with the synthetic cathinones individually and in
combination. Thus, to determine whether the enhanced DA response following coadministration of MDPV, mephedrone, and methylone had any measurable effects on
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the psychostimulant properties of the individual drugs, locomotor activity experiments
were conducted in mice treated with intermittent 10 mg kg-1 doses of MDPV,
mephedrone, or the cathinone cocktail. Mephedrone was chosen as the representative
substrate cathinone for individual analysis as it is reported to be more potent than
methylone at inducing DAT-mediated DA release and producing hyperactivity in rodents
(Baumann et al., 2012; Bonano et al., 2014). In agreement with several studies
(Baumann et al., 2013; Fantegrossi et al., 2013; Marusich et al., 2012), we found that
MDPV induced profound forward locomotion after a single 10 mg kg-1 treatment, while
repeated exposure at this dose appeared to induce focused stereotypy, evidenced by a
trending increase in immobility episodes. Observed stereotypies included self-licking
and repetitive hindlimb jumping, which have been previously reported with MDPV
(Fantegrossi et al., 2013). In the present study, mephedrone (10 mg kg-1) did not
influence the locomotor or stereotypic responses of mice on either treatment day,
despite findings of significant dopaminergic effects. These results are in agreement with
some studies (Budzynska et al., 2015; Motbey et al., 2012), but are different than others
(Baumann et al., 2012; Lisek et al., 2012; Shortall et al., 2013). However, given the fact
that activity testing began 15 min post injection, it is conceivable that the stimulant
effects of mephedrone had already peaked and returned to near baseline by the time
testing began. Although this would not be predicted from pharmacokinetic data in our
lab, it is consistent with the various reports that mephedrone produces transient
stimulant effects that are rapid in onset (within 10 min) and short in duration (Aarde et
al., 2013; Kehr et al., 2011; Marusich et al., 2012; Šíchová et al., 2017) and coincides
with the described short-lasting effects of this drug by recreational users (Dargan et al.,
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2011; Winstock et al., 2011). Additionally, given the potent serotonergic effects of
mephedrone (Baumann et al., 2012; Kehr et al., 2011), locomotor activation may have
been dampened due to enhanced 5-HT neurotransmission in the STR and NAc.
Combined 10 mg kg-1 administration of MDPV, mephedrone, and methylone
induced profound evidence of stereotypic activity (high immobility counts) that was
accompanied by significantly depressed forward locomotion after both acute and
repeated dosing. Observed stereotypies included head bobbing and self-injurious chest
biting, often resulting in skin wounding and bleeding. Similar effects have been reported
following a single high dose treatment of methamphetamine (Gentry et al., 2004;
Kuczenski and Segal, 1997; Segal and Kuczenski, 1987) and MDPV (30 mg kg-1)
(Fantegrossi et al., 2013); however, none of the individual cathinones were shown by
this study or others (Gregg and Rawls, 2014; Gregg et al., 2013b; López‐Arnau et al.,
2012; Shortall et al., 2013) to produce acute stereotyped motor deficits at 10 mg kg-1
doses. Thus, the motor-stimulant responses of the individual drugs are significantly
altered when they are co-administered as a cocktail. As drug-induced increases in
extracellular DA in the accumbens and, in particular, the striatum have been positively
correlated to stereotypic responses (Budygin et al., 2000; Carr and White, 1987; Presti
et al., 2003), these data support our neurochemical findings. Additionally, motor deficits
in mice were exaggerated over time, with a greater degree of hypolocomotion on day 7
compared to day 1, while stereotypic activity was similar for both treatment days.
However, because stereotypy counts corresponded to immobility episodes lasting more
than 3 seconds, it is likely that these animals did, in fact, exhibit intensified stereotypic
activity by remaining in each stereotypic episode for longer periods of time, resulting in
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less ambulatory activity between episodes and the observed enhancement of
hypolocomotion on day 7. While more precise testing parameters should be used to
define this behavior, these data suggest that locomotor activity decreases with the
cathinone cocktail due to an increase in stereotypic behavior.
In sum, we have shown that acute MDPV, mephedrone, and methylone induce
large DA elevations within the NAc, STR, SNpc, and VTA, which are accentuated when
the drugs are given in combination with one another. This effect appears to result from
synergistic drug interactions, as combined 3.3 mg kg-1 doses of MDPV, mephedrone,
and methylone increase mesolimbic and nigrostriatal DA to levels that were significantly
greater than those achieved by any of the drugs alone at 10 mg kg-1 doses. In support
of this, we also found that acute dosing of the cathinone cocktail induced robust
stereotypic behavior and hypolocomotion that was exacerbated after repeated dosing,
an effect that was not observed with the individual drugs and is consistent with
enhanced DA neurotransmission. Given that excessive DA release has been implicated
in methamphetamine neurotoxicity (Halpin et al., 2014) and is associated with its
significant reinforcing effects (Volkow and Morales, 2015), these findings raise concerns
about possible dopaminergic toxicity and addictive potential when MDPV, mephedrone,
and methylone are co-abused in bath salt mixtures.
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Supplementary Data
Table S1. Two-way ANOVAs for dose and treatment effects of MDPV, mephedrone,
and methylone and their combination on DA, DOPAC, HVA, and DA turnover
Brain Dependent Main effect
region variable
treatment
F(4,44) = 24.97
DA
P < 0.0001
F(4,43) = 7.09 P
DOPAC
< 0.0002
NAc
F(4,43) = 19.19
HVA
P < 0.0001
DA
F(4,43) = 19.70
turnover
P < 0.0001
DA

STR

DOPAC
HVA
DA
turnover
DA
DOPAC

VTA
HVA
DA
turnover
DA
DOPAC
SNpc
HVA
DA
turnover

Main effect
dose
F(1,44) = 38.76
P < 0.0001
F (1,43) = 0.09
P > 0.05 (ns)
F(1,43) = 30.30
P < 0.0001
F(1,43) = 36.80
P < 0.0001

Interaction
F(4,44) = 5.27
P < 0.0015
F(4,43) = 3.54
P < 0.0146
F(4,43) = 8.97
P < 0.0001
F(4,43) = 2.60
P < 0.05

F(4,43) = 42.76
P < 0.0001

F(1,43) = 101.5
P < 0.0001

F(4,43) = 18.20
P < 0.0001

F(4,43) = 5.83 P
< 0.0008
F(4,44) = 54.87
P < 0.0001
F(4,43) = 22.63
P < 0.0001
F(4,42) = 45.44
P< 0.0001
F(4,42) = 12.14
P < 0.0001
F(4,42) = 19.77
P < 0.0001
F(4,42) = 30.20
P < 0.0001
F(4,42) = 23.74
P< 0.0001
F(4,42) = 9.87 P
< 0.0001
F(4,42) = 10.64
P < 0.0001
F(4,42) = 36.33
P < 0.0001

F (1,43) = 2.39
P > 0.05 (ns)
F (1,44) = 16.71
P < 0.0001
F(1,43) = 42.85
P < 0.0001
F(1,42) = 37.71
P < 0.0001
F(1,42) = 36.38
P < 0.0001
F(1,42) = 3.12
P > 0.05 (ns)
F(1,42) = 23.26
P < 0.0001
F(1,42) = 15.10
P < 0.0004
F(1,42) = 29.97
P < 0.0001
F(1,42) = 2.68
P > 0.05 (ns)
F(1,42) = 50.93
P < 0.0001

F(4,43) = 8.86
P < 0.0001
F(4,44) = 11.86
P < 0.0001
F(4,43) = 3.05
P <0.0261
F(4,42) = 4.27
P < 0.0055
F(4,42) = 4.46
P < 0.0044
F(4,42) = 5.18
P < 0.0017
F(4,42) = 2.90
P < 0.0331
F(4,42) = 3.55
P < 0.0138
F(4,42) = 3.08
P < 0.0259
F(4,42) = 5.49
P < 0.0012
F(4,42) = 8.60
P < 0.0001
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Table S2. Post-hoc statistical comparisons (Bonferroni test for multiple comparisons) for
mice treated with MDPV, mephedrone, methylone, and the cathinone cocktail
Comparison

DA

MDPV 1 vs control
MDPV 10 vs control
Meph 1 vs control
Meph 10 vs control
Methy 1 vs control
Methy 10 vs control
Combo 1 vs control
Combo 3.3 vs control
MDPV 1 vs Combo 1
Meph 1 vs Combo 1
Methy 1 vs Combo 1
MDPV 10 vs Combo 3.3
Meph 10 vs Combo 3.3
Methy 10 vs Combo 3.3
Meph 1 vs MDPV 1
Methy 1 vs MDPV 1
Meph 10 vs MDPV 10
Methy 10 vs MDPV 10

ns
***
ns
*
ns
*
***
***
**
**
**
*
***
***
ns
ns
***
**

MDPV 1 vs control
MDPV 10 vs control
Meph 1 vs control
Meph 10 vs control
Methy 1 vs control
Methy 10 vs control
Combo 1 vs control
Combo 3.3 vs control
MDPV 1 vs Combo 1
Meph 1 vs Combo 1
Methy 1 vs Combo 1
MDPV 10 vs Combo 3.3
Meph 10 vs Combo 3.3
Methy 10 vs Combo 3.3
Meph 1 vs MDPV 1
Methy 1 vs MDPV 1
Meph 10 vs MDPV 10
Methy 10 vs MDPV 10

ns
***
ns
*
ns
ns
**
***
*
*
**
***
***
***
ns
ns
***
***

DOPAC
NAc
ns
ns
ns
*
ns
**
ns
ns
ns
ns
ns
ns
*
**
ns
ns
***
***
STR
ns
ns
ns
*
ns
**
ns
*
ns
ns
ns
ns
***
***
ns
ns
***
***
VTA
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HVA

DA turnover

*
***
ns
***
ns
**
***
**
ns
*
**
***
ns
ns
ns
ns
***
***

ns
**
ns
**
ns
***
**
***
*
*
ns
***
***
ns
ns
ns
ns
ns

ns
***
*
***
ns
***
ns
***
ns
ns
ns
***
ns
ns
ns
ns
***
***

ns
***
ns
***
ns
**
***
***
***
**
***
ns
**
***
ns
ns
ns
ns

MDPV 1 vs control
MDPV 10 vs control
Meph 1 vs control
Meph 10 vs control
Methy 1 vs control
Methy 10 vs control
Combo 1 vs control
Combo 3.3 vs control
MDPV 1 vs Combo 1
Meph 1 vs Combo 1
Methy 1 vs Combo 1
MDPV 10 vs Combo 3.3
Meph 10 vs Combo 3.3
Methy 10 vs Combo 3.3
Meph 1 vs MDPV 1
Methy 1 vs MDPV 1
Meph 10 vs MDPV 10
Methy 10 vs MDPV 10

ns
***
ns
***
ns
**
***
***
***
***
***
***
***
***
ns
ns
ns
ns

**
*
ns
ns
***
ns
ns
**
***
ns
***
ns
ns
***
*
ns
**
ns

***
**
*
**
*
**
***
***
ns
***
***
ns
ns
ns
***
***
ns
ns

**
***
***
***
*
***
***
***
ns
ns
*
ns
ns
*
ns
ns
ns
ns

ns
***
**
***
ns
***
ns
**
ns
**
ns
ns
ns
ns
ns
***
ns
ns

***
***
ns
***
***
*
**
ns
ns
ns
ns
*
**
ns
ns
**
ns
ns

**
***
ns
***
ns
*
***
***
**
***
***
ns
ns
***
**
ns
*
***

SNpc
MDPV 1 vs control
MDPV 10 vs control
Meph 1 vs control
Meph 10 vs control
Methy 1 vs control
Methy 10 vs control
Combo 1 vs control
Combo 3.3 vs control
MDPV 1 vs Combo 1
Meph 1 vs Combo 1
Methy 1 vs Combo 1
MDPV 10 vs Combo 3.3
Meph 10 vs Combo 3.3
Methy 10 vs Combo 3.3
Meph 1 vs MDPV 1
Methy 1 vs MDPV 1
Meph 10 vs MDPV 10
Methy 10 vs MDPV 10

***
ns
**
ns
ns
ns
***
***
*
***
*
***
***
***
*
ns
ns
*

Mice were treated with MDPV, mephedrone, methylone, or their combination at varied
doses (represented by the numerals after each drug). Drug treatment induced changes
in DA and HVA were increases by comparison to control. Treatment induced changes in
DOPAC and DA turnover were decreases by comparison to control. Significance levels
for the comparisons are indicated by * p < 0.05, ** p < 0.01, and *** p < 0.001.
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Table S3. One-way ANOVAs for the treatment effects of the cathinone cocktail at 1 mg
kg-1, 3.3 mg kg-1, and 10 mg kg-1
Brain region

Main effect of treatment on DA

NAc

F(4) = 50.27 P < 0.0001

STR

F(4) = 42.92 P < 0.0001

VTA

F(4) = 17.84 P < 0.0001

SNpc

F(4)= 26.95 P < 0.0001

Table S4. Post-hoc statistical comparisons (Tukey’s multiple comparisons) for mice
treated with the cathinone cocktail at 1 mg kg-1, 3.3 mg kg-1, and 10 mg kg-1.
Comparison

NAc (DA
levels)
Combo 10 vs Combo 1 ***
Combo 10 vs Combo 3 ns
Combo 10 vs control
***
Combo 3 vs Combo 1
***

STR (DA
levels)
***
ns
***
***

VTA (DA
levels)
ns
ns
***
ns

SNpc (DA
levels)
*
ns
***
*

The effects of the cathinone cocktail at three different doses on tissue DA are presented
in Fig 3.3, and levels of significance are indicated as * p < 0.05, ** p < 0.01, and *** p <
0.001 by each treatment comparison. The effects of 1 mg kg-1 and 3.3 mg kg-1 combo
by comparison to controls are listed in Table S2 and have not been included here.
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Introduction
The synthetic cathinones, 3, 4-methylenedioxypyrovalerone (MDPV), 4methylmethcathinone (mephedrone), and 3, 4-methylenedioxymethcathinone
(methylone), are major constituents of bath salt mixtures and continue to be one of the
most prevalent classes of designer drug compounds. Despite DEA classification of
MDPV, mephedrone, and methylone as schedule I controlled substances in 2011(DEA,
2011), international control laws remain lacking and abuse continues to thrive with the
internet serving as a clandestine marketplace for these drugs (Coppola and Mondola,
2012; Dybdal-Hargreaves et al., 2013; Karila et al., 2015). Bath salts are described by
users to precipitate desirable psychostimulant and hallucinogenic effects; however,
violent behavior, tachycardia, respiratory distress, seizures, and even death have also
been reported with their abuse (DEA, 2011; Karch, 2015; Prosser and Nelson, 2012).
In recent years, great strides have been made in our understanding of the
pharmacology and abuse liability of synthetic cathinones; however, descriptions of their
neurotoxic properties remain limited. Moreover, while much of the preclinical data on
synthetic cathinones explicates the individual effects of MDPV, mephedrone, and
methylone, forensic analysis and DEA case reports have indicated that bath salt
products contain various mixtures of MDPV, mephedrone, and methylone with each
other or other stimulant substances (Araujo et al., 2015; DEA, 2011; Spiller et al., 2011).
Also, a retrospective search of records involving synthetic cathinones at two poison
control centers revealed that many of most frequently abused bath salt ‘brands,’
identified by patient history reports, contained mixtures of MDPV, mephedrone, and
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methylone (Spiller et al., 2011; Warrick et al., 2013). Thus, to better model bath salt
abuse, the effects of synthetic cathinone mixtures should be assessed.
MDPV is a catecholamine selective monoamine transporter blocker that was
found to be significantly more potent than cocaine at inhibiting synaptic clearance of
dopamine (DA), increasing extracellular DA, and stimulating locomotor activity
(Baumann et al., 2013). Mephedrone and methylone behave as substrates at
monoamine transporters and exhibit transporter-mediated DA and serotonin (5-HT)releasing effects similar to their non-beta keto analogs, methamphetamine (METH) and
3,4 methylenedioxymethamphetamine (MDMA) (Baumann et al., 2012; López‐Arnau et
al., 2012). Additionally, mephedrone and methylone induce locomotion and fully
substitute for METH and MDMA in drug discrimination studies (Bonano et al., 2014;
Gatch et al., 2013; Harvey and Baker, 2016), further suggesting shared
pharmacological activity between these drugs. However, the substrate synthetic
cathinones produce unique effects with regards to DA neurotoxicity. While neither
mephedrone nor methylone induce damage to DA nerve endings (Angoa-Perez et al.,
2016; Angoa-Perez et al., 2012), they accentuate the neurotoxic effects of METH,
amphetamine (AMPH), and MDMA when co-administered with these drugs (AngoaPérez et al., 2014; Angoa‐Pérez et al., 2013; Anneken et al., 2015). While the
underlying mechanism of the effect has not been determined, these findings suggest
that the neurotoxic properties of the synthetic cathinones are enhanced when they are
combined with other drugs that target the dopamine transporter (DAT). However,
preclinical investigations of the combined effects of MDPV, mephedrone, and methylone
on measures of neurotoxicity are extremely limited. To address this lack of experimental
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data, the present study evaluated the effects of ternary mixtures of MDPV, mephedrone,
and methylone on DA and major proteins of the dopaminergic synapse in mice. The
effect of these drug cocktails on neuroinflammatory markers and DA neuron counts was
also assessed.
Materials and Methods
Drugs and Reagents
MDPV ((±) 3, 4-methylenedioxypyrovalerone HCl), mephedrone ((±) 4methylmethcathinone HCl), and methylone ((±)3, 4-methylenedioxymethcathinone HCl)
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Certified reference standard
grade dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid
(HVA) , and 3,4- dihydroxybenzlyamine hydro-bromide (DHBA) were also purchased
from Sigma-Aldrich. The ion pairing agent, sodium octyl sulfate (SOS), was purchased
from Acros organics (Geel, Belgium) and 2.0 N perchloric acid was purchased from
RICCA chemical (Arlington, TX, USA). All other certified ACS chemicals and buffer
reagents used in this study were purchased from Thermo Fisher Scientific (Fair Lawn,
NJ, USA).
Animals
The experiments utilized adolescent male Swiss-Webster mice (Harlan Inc.,
Indianapolis, IN) weighing 20-30 g. Male adolescent mice were chosen for this study as
drug survey reports suggest the main abusers of synthetic cathinones are young male
adults (Karila et al., 2015; Vardakou et al., 2011; Winstock et al., 2011). The animals
were housed in a full AAALAC-accredited facility under standard laboratory conditions
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(22 ± 1°C, 12 h light/dark cycle) with food and water freely available. The experimental
protocol was approved by the ETSU University Committee on Animal Care (UCAC),
following the National Institutes of Health Guidelines for the Care and Use of Laboratory
Animals.
Animal Treatment
Mice (age 40 days) were weighed and separated into the following treatment groups: 1)
saline (controls), 2) MDPV (10 mg kg-1), 3) mephedrone (10 mg kg-1), 4) methylone (10
mg kg-1), and 5) cathinone cocktail (10 mg kg-1MDPV + 10 mg kg-1 mephedrone + 10
mg kg-1 methylone). The total cathinone dose used in the cocktail (30 mg kg-1 total
cathinones) was chosen based on previous experiments reporting that 30 mg kg-1
injections of synthetic cathinones produced physiological responses commonly
associated with psychostimulant neurotoxicity (den Hollander et al., 2013). All treatment
groups were utilized for neurochemical analysis. In protein expression assays,
mephedrone was chosen over methylone as the representative substrate cathinone due
to its increased potency and DA-releasing capabilities at the DAT (Baumann et al.,
2012; Simmler et al., 2013); thus, all treatment groups except methylone were analyzed.
For chronic dosing, each animal received intraperitoneal (IP) injections according to
their treatment group every other day for 14 days (7 injections total). All drugs were
dissolved in saline and injected at a volume of 0.01 ml/g body weight; equal volumes of
saline were used to treat control animals. This every other day dosing schedule follows
the paradigm described by Pierce and Kalivas (1997), by which 48 h drug dosing allows
for complete drug wash out prior to each injection, and has been traditionally used with
psychostimulant studies.
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Tissue Collection
For neurochemical and protein expression assays, mice were anesthetized with
isoflurane and euthanized by decapitation 2 days after drug treatment. This point was
chosen based on previous studies indicating that amphetamine-associated neurotoxicity
reaches maximum at 2 days (Angoa‐Pérez et al., 2013). Brains were collected
immediately and placed in ice cold saline for 5 min. The nucleus accumbens (NAc),
striatum (STR), substantia nigra pars compacta (SNpc), and ventral tegmental area
(VTA) were dissected from each brain based upon coordinates in the mouse brain atlas
(Paxinos and Watson) using a 30g Coronal mouse brain matrix (ASI Instruments), flash
frozen, and stored at -70°C until further analysis. For immunohistochemistry, mice were
deeply anesthetized with Avertin (2.5% tribromoethyl alcohol in 0.9% saline), identified
via the loss of deep tendon and corneal reflexes, and transcardially perfused with ice
cold 3 % paraformaldehyde. Fixed brains were then dehydrated in ethanol, incubated in
xylene, and embedded in paraffin (Paraplast-X-tra™, Fisher Scientific). Brains were
blocked, sectioned on the microtome at 10 µM thickness, and mounted onto Superfrostplus slides (Fisher Scientific). Every section from the rostral hippocampus to the anterior
cerebellar-midbrain junction (Bregma: -2.70 to -3.70, Paxinos and Watson) was seriallycollected and mounted at five sections per slide.
Neurochemical Analysis
Concentrations of DA and relevant metabolites, DOPAC and homovanillic acid (HVA),
were measured in discrete brain tissue extracts using a previously described method
employing HPLC with electrochemical detection (Allen et al., 2017). Briefly, samples
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were homogenized in methanol, spiked with the internal standard (3,4Dihydroxybenzylamine (DHBA)), and centrifuged at 14,000 x g. Collected supernatants
were dried under nitrogen gas, and reconstituted in 0.2 N perchloric acid.
Chromatographic separations were achieved using a C18 MD- 150 mm x 3.2 mm, 3 µm
column (Thermo Fisher Scientific, Sunnyvale, CA, USA), with a mobile phase consisting
of 95% 50 mM sodium acetate, 10 mM citric acid, 0.38 mM SOS, 0.15 mM EDTA, and
5% acetonitrile. Electrochemical detection was performed using a Coulochem® III
detector (ESA Laboratories, Inc.) equipped with 5100A dual electrode. Data were
collected on-line and exported to an Agilent EZChrome Elite software system (Santa
Clara, CA, USA) for peak integration and analysis. On the day of analysis, standard
calibration solutions containing 0.125 - 30 ng/mL were prepared in 0.2 N perchloric acid
and used to generate five-point internal standard calibration curves for each analyte.
Peak area ratios were used for computations, and analyte concentrations were
calculated using interpolation of their respective standard curves.
Protein Expression Assays
Tissue lysate preparation. Collected brain tissue regions were suspended in
appropriate amounts of ice cold isolation buffer consisting of RIPA lysis buffer and MSSAFE protease and phosphatase inhibitor cocktail (1:10, Sigma Aldrich). Cells in tissue
samples were lysed by 30 seconds of sonication with an ultrasonic processor, and
cellular debris were removed via centrifugation at 4°C at 14,000 X g for 15 min.
Supernatant concentration was measured on an Epoch 2 microplate reader (BioTek,
Winooski, VT, USA) using the Pierce Bradford Protein assay kit (Thermo Scientific).
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Simple Western analysis. Expression levels of the dopamine transporter (DAT-1),
tyrosine hydroxylase (TH), monoamine oxidase B (MAO-B), catechol-Omethyltransferase (COMT), vesicular monoamine transporter (VMAT2), glial fibrillary
acidic protein (GFAP) and loading control glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) were measured in lysates using the capillary-based, automated Western
blotting system, ‘Wes’ from ProteinSimple (Santa Clara, CA, USA). The primary
antibodies and dilutions used for these analyses were Rabbit anti-DAT 1 (1:25, Abcam),
Rabbit anti-TH (1:1000, Novus Biologicals), Rabbit anti- MAO-B (1:10, Novus
Biologicals), Rabbit anti- COMT (1:10, Novus Biologicals), Rabbit biotin conjugated antiVMAT2 (1:1000, Novus Biologicals), Rabbit anti-GFAP (1:100, Dako) and Rabbit antiGAPDH (1:1000, Novus Biologicals). Size-based assays were performed using Wes 12230 kDa rabbit master kit reagents according to the user manual (PS-MK14,
ProteinSimple). Briefly, samples were diluted with 0.1 X sample buffer (ProteinSimple)
to achieve a final concentration of 100 µg/mL (DAT-1) or 250 µg/mL (TH, MAO-B,
COMT, VMAT2, GFAP), (amount of total protein content determined from Bradford
assay (ug/mL)). Diluted samples were then mixed with a master mix (ProteinSimple)
containing fluorescent molecular weight markers and 40 mM dithiothreitol (DTT), and
heated at 95°C for 5 min. Denatured samples, blocking reagent, primary antibodies,
HRP-conjugated anti-rabbit secondary antibodies (streptavidin-HRP for VMAT2), and
chemiluminescent substrate were dispensed into designated wells of a manufacturer
supplied microplate, pre-loaded with separation and stacking matrices. Prepared assay
plates were then loaded into Wes and analyzed at room temperature using the
instrument default settings. Chemiluminescent protein bands were captured by a
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charge-coupled device (CCD), and the digital image was analyzed using inline
Compass software (ProteinSimple). Relative band densities of all proteins were
normalized to the GAPDH level for each lane.
Cell Culture and Cytotoxicity Assay
The SH-SY5Y cell line was obtained from the ATCC. Cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin. Cells were maintained at 37°C, saturated humidity, and 5%
CO2. Cells were plated onto 24-well culture plates at a density of 1 × 105 cells/well and
differentiated in reduced serum media (3% FBS) supplemented with 10µM retinoic acid
for six days prior to experimentation. SH-SY5Y cells were treated with vehicle, 1 mM
MDPV, 1 mM mephedrone, 3 mM mephedrone, 1 mM methylone, or the cathinone
cocktail (1 mM MDPV + 1 mM mephedrone + 1 mM metylone) and cytotoxicity was
determined at 6, 12, 24, and 48 h after drug application by measuring the activity of the
lactate dehydrogenase released into the culture media according to the manufacturer’s
protocol (BioVision, K311-400). Treatment doses were similar to those previously
utilized with the synthetic cathinones in SH-SY5Y cells (den Hollander et al., 2014;
Rosas-Hernandez et al., 2016; Valente et al., 2017). Samples were done in triplicate
and assessed in reference to a 1% Triton-X treated control.
Immunohistochemistry
Deparaffinized sections were incubated with rabbit polyclonal anti-TH (Pel-Freeze
Biologicals; 1:250) overnight for identification of TH positive dopamine neurons. TH
positive cells were visualized using the avidin biotin complex (ABC) reaction and
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diaminobenzindine (DAB) substrate solution kits (Vector laboratories). All sections were
counterstained with the nissl stain Neutral Red (Sadasivan et al., 2012).
Quantification of TH-positive neurons. A model-based stereological method was
used to estimate the total number of DA neurons within the SNpc sections (Baquet et
al., 2009). Briefly, TH-positive and TH-negative cells of the DA phenotype were counted
from both the right and left sides of one SNpc section per slide using a 40x objective.
The same section was counted on each slide, and the Abercrombie correction factor
(Abercrombie, 1946) was used to correct for split nuclei.
Data Analysis
All statistical analyses were performed using GraphPad Prism version 5.0 for Windows
(GraphPad Software, San Diego, CA, USA). LDH data were analyzed using a two-way
ANOVA followed by Bonferroni’s post-hoc test. The effect of each drug treatment on
tissue DA, DOPAC, HVA, levels and relative expression levels of DAT, TH, MAO-B,
COMT, VMAT2, and GFAP were tested for significance using one-way ANOVA,
followed by Tukey’s post-hoc test. DA turnover values were calculated as
[DOPAC+HVA]/[DA], and the effect of treatments on DA turnover were evaluated by
one-way ANOVA followed by Tukey’s post-hoc test. The effect of combined cathinone
treatment on DA neuron number was compared to saline by an unpaired t-test. The
minimum criterion for statistical significance was P < 0.05.
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Results
Effects of Chronic Individual and Combined Synthetic Cathinone Exposure on
Mesolimbic and Nigrostriatal DA Concentration and Turnover
Dopamine concentration and turnover rates within discrete brain regions of mice
chronically treated with the synthetic cathinones, alone and in combination, are
presented in Figure 4.1 and 4.2, respectively. The main effect of treatment on DA and
DA turnover values was highly significant (p < 0.001- < 0.0001). Statistical analyses
revealed significant increases in DA levels above control within all brain areas 2 days
after repeated individual exposure to MDPV and mephedrone, with methylone,
significantly increasing NAc and VTA DA levels. Moreover, MDPV produced the
greatest elevation of DA levels in the nerve terminal regions when compared to
mephedrone (p < 0.001) and methylone (p < 0.001) (Fig 4.1A). Conversely, DA levels
were significantly reduced in the NAc, STR, SNpc, and VTA brain regions of mice 2
days after chronic treatment with cathinone cocktail, as compared to saline control
animals (Fig 4.1A). The cathinone cocktail significantly increased DA turnover in all
brain areas. The individual cathinones induced similar significant increases in accumal
and striatal DA turnover, with MDPV additionally increasing DA turnover in the VTA (Fig
4.1B).
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Figure 4.1 DA concentration (A) and turnover (B) in the NAc, VTA, STR, and SNpc
following chronic dosing of MDPV, mephedrone, and methylone individually and in
combination. Monoamine and metabolite levels were determined using HPLC analysis
and are reported as % of control. Data are expressed as means for n = 4 - 6 mice per
group ± SEM (< 5% of means). * p < 0.05, ** p < 0.01, *** p < 0.001 vs control (saline).

Effects of Chronic Synthetic Cathinone Exposure on DA Degradation and Biochemical
Markers of Neurotoxicity
MAO-B and COMT. Given the ability of amphetamine-like compounds to inhibit
DA degradative enzymes, synthetic cathinones were evaluated for their individual and
combined ability to dysregulate MAO-B and COMT expression levels (Fig 4.2). MDPV
alone did not change the levels of MAO-B and COMT in any of the studied brain
regions. Mephedrone treatment had no significant effects on MAO-B, but produced
significant decreases in COMT in all regions examined (Fig. 4.2B). In contrast,
significant reductions in both MAO-B and COMT levels were observed in all brain
regions of mice treated with the cathinone cocktail (Fig 4.2A,B).
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Figure 4.2 Relative expression levels of MAO-B and COMT in the mesolimbic and
nigrostriatal brain pathways following repeated dosing of MDPV, mephedrone, and the
cathinone cocktail (MDPV + mephedrone + methylone). Relative pixel densities were
quantified using ProteinSimple compass software and were normalized to GAPDH.
Data are means for n = 4 - 6 mice per group, ± SEM. * p < 0.05, ** p < 0.01, *** p <
0.001 vs. saline.

VMAT2. To assess the effects of repeated synthetic cathinone exposure on
intracellular DA storage mechanisms, a target of METH and other amphetamines,
protein expression levels of VMAT2 were determined in mice chronically treated with
the synthetic cathinones. As shown in Figure 4.3, enhanced striatal VMAT2 expression
was observed following exposure to the cathinone cocktail and MDPV, while
mephedrone and MDPV treatment reduced expression in the VTA.
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Figure 4.3 Relative expression level of VMAT2 in the NAc, VTA, STR, and SNpc of
mice repeatedly administered MDPV, mephedrone, or the cathinone cocktail. Data are
expressed as group means ± SEM, n = 4 – 6 per group. * p < 0.05, ** p < 0.01, *** p <
0.001 vs. saline.

DAT-1 and TH. To further investigate if chronic bath salt exposure affects the
integrity of dopaminergic nerve terminals, expression of DAT-1 and TH, two major
dopaminergic neuronal markers, were analyzed by ProteinSimple western blot analysis
following repeated synthetic cathinone exposure (Figure 4.4). Statistical analysis
showed significant reductions in mesolimbic and nigrostriatal DAT-1 levels following
treatment with the cathinone cocktail, while only striatal reductions of DAT -1 were
observed following individual exposure to MDPV and mephedrone (Fig 4.4A). Moreover,
TH levels were significantly decreased in all brain regions of mice treated with the
cathinone cocktail, as well as mephedrone alone (Fig 4.4B). Conversely, individual
MDPV treatment significantly increased TH in all brain regions (Fig 4.4B).
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Figure 4.4 Effects of chronic exposure to MDPV, mephedrone, and the cathinone
cocktail (10 mg kg-1) on the relative expression levels of DAT-1 (A) and TH (B) in mice
48 h after dosing. Protein levels were normalized to GAPDH and are expressed at
group means (n = 4 – 6) ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. saline.

Cytotoxic Effects of Synthetic Cathinones
The effects of the synthetic cathinones alone and in combination on LDH release over a
48 h time course are shown in Figure 4.5. The main effects of synthetic cathinone
treatment, time after application, and their interaction were all highly significant (p <
0.0001). Post-hoc analysis revealed that all treatment groups increased LDH release
over time (Fig 4.5A). Mephedrone (1 mM and 3 mM) and the cathinone cocktail
significantly increased LDH release at all studied time points (6, 12, 24, and 48 h), while
MDPV and methylone treatment significantly increased LDH release at 12, 24, and 48 h
after exposure. Moreover, treatments including mephedrone trended significantly higher
than either MDPV or methylone treatments, while LDH release due to 1 mM MDPV + 1
mM mephedrone + 1 mM methylone treatment was significantly greater than those
observed with any of the individual drug treatments at 24 h and 48 h (Fig 4.5B).
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Figure 4.5 LDH leakage induced by MDPV, mephedrone, and methylone individually
and in combination in dopaminergic SH-SY5Y cells 6, 12, 24, and 48 h after drug
exposure (A). Experiments were performed in triplicate and the mean effects were
normalized to Triton-X positive controls and untreated negative controls at each time
point. (B) Represents all drug treatments at 48 h. *** p < 0.001 vs. control values, # p <
0.05 vs. combo (B).

Effects of Chronic Combined Administration of MDPV, Mephedrone, and Methylone on
Neuroinflammation and Nigral DA Neuron Number
Glial reactivity. GFAP levels were measured in the striatum of mice chronically
administered MDPV, mephedrone, methylone, or the cathinone cocktail to determine if
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the synthetic cathinones induce neuroinflammatory responses at DA nerve terminals
similar to other neurotoxic amphetamine derivatives. Data are presented in Fig 5 A.
Treatment with MDPV, methylone, or the cathinone cocktail did not alter GFAP
expression in regards to control, while striatal GFAP was significantly increased in the
mephedrone treatment group.
DA neuron counts. To definitively assess the toxicity of drug mixtures containing
MDPV, mephedrone, and methylone on DA neurons, systematic stereological analysis
of TH-positive cells in the SNpc of mice treated with either saline or the cathinone
cocktail was performed. As shown in Fig 5B, chronic exposure to the cathinone cocktail
did not affect the number of TH-positive DA neurons in the SNpc.
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Figure 4.6 The effects of combined synthetic cathinone exposure on nigrostriatal
toxicity. Mice were chronically treated with MDPV, mephedrone, or the cathinone
cocktail and striatal levels of GFAP were determined 2 days later (A). GFAP levels were
normalized to GAPDH and data are means for n = 4 – 6 mice per group (± SEM).
Additionally, TH+ neurons were stained and counted in serial sections of the SNpc of
mice repeatedly dosed with the MDPV + mephedrone + methylone cocktail (B). A nissl
counter stain was used for landmark identification and data are expressed at group
means ± SEM (control n = 2, combo n = 6).
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Discussion
The primary aim of the present study was to investigate the chronic effects of
ternary mixtures of MDPV, mephedrone, and methylone on dopaminergic tone. While
DEA statistics and numerous case reports indicate that many of the most commonly
abused bath salt ‘brands’ contain various mixtures of these compounds (Araujo et al.,
2015; Spiller et al., 2011), the majority of pre-clinical investigations on bath salts have
focused on characterizing the effects of the individual constitutes. Therefore, the
rationale for analyzing the combined action of MDPV, mephedrone, and methylone on
monoaminergic systems is compelling. Here, we have shown that chronic dosing of
MDPV, mephedrone, or methylone alone induces prolonged DA elevations throughout
the reward and motor control brain pathways. These data are supported by previous
studies demonstrating that binge dosing regimens of cathinone, mephedrone, and
methylone produce long-lasting elevations in extracellular DA levels (Angoa-Perez et
al., 2012; Banjaw et al., 2003; López‐Arnau et al., 2012), as well as studies reporting
that MDPV administration precipitates persistent rises in extracellular DA and stimulates
locomotor responses that persist for extended periods of time (Baumann et al., 2013;
Schindler et al., 2016; Simmler et al., 2013).
Additionally, these persistent DA elevations appear to be associated with
dysregulated expression of major DA regulatory proteins. Notably, repeated dosing of
MDPV was accompanied by increased expression levels of the DA synthesis enzyme,
tyrosine hydroxylase (TH), in all four brain regions. Given the potent blockade of DA
reuptake by MDPV this is not surprising; cytosolic DA levels are depleted and increased
TH densities may represent a compensatory mechanism for this effect (Vrana et al.,
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1993). In contrast, decreased TH expression was observed in the DA nerve terminal
regions of mice treated with mephedrone; however, the DA degradative enzyme COMT
was also downregulated. These data are in support of previous findings indicating that
mephedrone downregulates striatal TH levels (Lopez-Arnau et al., 2015) and causes
long-term depletions in the COMT metabolite, homovanillic acid (HVA) (den Hollander
et al., 2013). While COMT primarily functions to degrade DA and DOPAC, it can also
degrade the DA precursor molecule, L-DOPA (Jones et al., 1998); thus, suppressed
expression of COMT may contribute to the observed elevations in DA after repeated
exposure to mephedrone by inhibiting degradation of both DA and the DA biosynthetic
precursor molecule L-DOPA. Additionally, while mephedrone-induced reductions in TH
have previously been suggested as evidence of its toxicity (Lopez-Arnau et al., 2015),
we have shown here that this substrate cathinone can decrease TH without
concurrently reducing DA and DAT. Thus, reduced TH expression may not be indicative
of mephedrone toxicity.
Notably, repeated co-exposure to MDPV, mephedrone, and methylone
significantly reduced mesolimbic and nigrostriatal tissue levels of DA, TH, and DAT
following a 48 h drug wash-out period. In addition, expression levels of MAO-B and
COMT were also significantly reduced. These results are in contrast with the individual
effects of MDPV and mephedrone and indicate a major dysregulation of the
dopaminergic system when these compounds are co-abused in bath salt mixtures. As
persistent depletions in DA and decreased expression of TH and DAT are well accepted
gauges of neurotoxicity associated with chronic METH abuse (Cadet et al., 2007; Halpin
et al., 2014), these data suggest that repeated co-abuse of bath salt constituents
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MDPV, mephedrone, and methylone, effectuates damage to dopaminergic nerve
terminals. Therefore, it may be the case that while these compounds do not induce
blatant DA toxicity individually, their co-abuse in bath salt mixtures produces potentially
damaging interactions at dopaminergic terminals. This is supported by recent
investigations that have described enhanced neurotoxicity when the synthetic
cathinones were combined with other DAT-targeting drugs (Angoa‐Pérez et al., 2013;
Anneken et al., 2015). Additionally, recent studies have reported that self-administration
of binary mixtures of MDPV and methylone resulted in a high incidence of mortality (50
%), which was not observed with self-administration of either drug alone (Gannon et al.,
2018).
To further assess if combined exposure to synthetic cathinone compounds
enhances the toxic properties of individual drugs, LDH release assays were performed
using dopaminergic SH-SY5Y cells treated with MDPV, mephedrone, and methylone
alone and in combination. All three compounds significantly increased LDH release over
a 48 h time period. Notably, co-administration of MDPV, mephedrone, and methylone
exacerbated the cytotoxic effects of the individual drugs at both 24 and 48 h, suggesting
that the toxic properties of these drugs at DA nerve terminals are enhanced when they
are co-abused. To determine if this result was due to increased total synthetic cathinone
exposure in the cocktail, which contained 1 mM doses of each individual drug (3 mM in
total), a 3 mM dose of mephedrone was included in this study. Mephedrone dosedependently increases LDH release (den Hollander et al., 2014) and has been shown
by this study and others (den Hollander et al., 2014; Pantano et al., 2017; Valente et al.,
2017) to be more cytotoxic that both MDPV and methylone. Thus, the present finding
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that the cathinone cocktail (1 mM) produced a cytotoxic response that was significantly
greater than observed with 3 mM mephedrone at 24 and 48 h, supports the notion that
the synthetic cathinones are more toxic at DAT-expressing terminals when coadministered in a cocktail.
However, in contrast to neurochemical and cytotoxicity findings, we found that
chronic administration of the cathinone cocktail did not induce the loss of DA neurons in
the SNpc, an area susceptible to METH and MPTP-induced toxicity (Ares-Santos et al.,
2014; Thomas et al., 2004). While combined treatment may indeed promote
degeneration of DA nerve terminals, DA nuclei counts were not reduced. Additionally,
striatal levels of GFAP were not changed from control values in mice treated with the
cathinone cocktail. This lack of blatant neurotoxicity may be due to the weak effects of
mephedrone and methylone to increase cytosolic DA from vesicles in a VMAT2dependent manner (Eshleman et al., 2013; Green et al., 2014), or of full drug wash out
between doses, as METH toxicity is most notably observed following repeated, binge
dosing (Halpin et al., 2014). However, in light of these findings and the enhanced DA
responses with acute cocktail administration (Allen et al., in preparation), we suggest
that initial exposures to the cathinone cocktail produced large, prolonged increases in
DA that triggered a functional lesion in dopaminergic brain regions following later
exposures and drug-wash out. More specifically, the excessive accumulation of DA in
the synaptic cleft and enhanced DA receptor signaling triggers the downregulation of
DAT, TH, MAO, and COMT, and results in decreased DA levels. However, a more
detailed investigation regarding the downstream consequences of combined synthetic
cathinone exposure on DA signaling cascades would be required to confirm this notion.
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In summary, this study highlights the chronic neurochemical and biochemical
consequences of individual versus combined synthetic cathinone abuse. We have
shown that chronic individual exposure of MDPV, mephedrone, or methylone produced
long-term elevations in DA that were accompanied by either increased TH levels or
decreased COMT levels. In contrast, co-exposure of MDPV, mephedrone, and
methylone resulted in depleted brain tissue DA levels 48 h following repeated dosing.
We have also shown that these depletions are accompanied by decreased expression
of TH, DAT, MAO-B, and COMT. These data together with findings of enhanced
cytotoxicity with the cathinone cocktail, suggested a potential combined ability of MDPV,
mephedrone, and methylone to induce DA toxicity. However, because combined
treatment did not result in the loss of DA neurons in the SNpc or alter striatal GFAP
expression, this does not appear to be the case. Thus, it appears that the cathinone
cocktail may produce a “functional lesion,” downregulating many of the key players at
the dopaminergic synapse while not inducing blatant neurotoxicity. Most significantly,
this study has shown that the composition of bath salt mixtures can significantly
influence the dopaminergic and toxic effects of the individual constituents.
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CHAPTER 5
SUMMARY AND CONCLUSIONS
In recent years, the abuse of synthetic cathinone derivatives, popularized as
‘bath salts’ has become a public health threat. Despite the designation of the three most
prevalent synthetic cathinones, MDPV, mephedrone and methylone, as schedule I
controlled substances in 2011, abuse continues, with the internet serving as a central
marketplace for these compounds (DEA 2014; Karila et al. 2015). Forensic analysis of
bath salt products has revealed that many of the most popular bath salt ‘brands’ contain
binary and ternary mixtures of MDPV, mephedrone, and methylone; however, the
majority of preclinical investigations on these designer drug mixtures has focused on
elucidating the neurochemical and behavioral effects of each individual constituents
(Spiller et al. 2011). Thus, to better model bath salt abuse, the effect of synthetic
cathinone mixtures on the CNS should be assessed.
MDPV, mephedrone, and methylone possess similar chemical and
pharmacological characteristics to cocaine, methamphetamine, and MDMA. Namely,
MDPV inhibits DA reuptake through direct binding at DAT, similar to cocaine but with
greater potency (Baumann et al. 2013). Mephedrone and methylone behave as DAT
substrates and induce non-vesicular release of DA by reversing transporter flux,
resembling the actions of both METH and MDMA (Baumann et al. 2012). Given that
significant pharmacological interactions often occur following co-administration of drug
compounds that share a primary biological target, their individual mechanisms offer
opportunities for such interactions at monoamine transporters when taken together
(Tallarida 2011). Specifically, while both non-substrate (MDPV) and substrate
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(mephedrone and methylone) cathinones increase extracellular DA levels, the
dichotomy of their interaction at the DAT provides an avenue by which these drugs may
alter one another’s dopaminergic effect when co-abused.
While interactions between the synthetic cathinones themselves are not well
documented, evidence of enhanced neurotoxicity following co-exposure of the synthetic
cathinones with other amphetamine derivatives has recently been described (AngoaPérez et al. 2016). In this case, while neither mephedrone nor methylone damage DA
nerve endings, they accentuate the neurotoxic effects of METH, AMPH, and MDMA
when co-administered (Angoa‐Pérez et al. 2013; Anneken et al. 2015). While it could be
predicted that these non-toxic substrates would compete for DAT-mediated uptake and
thus weaken the toxic response of METH, AMPH, or MDMA, the findings in these
studies did not indicate that effect. Therefore, it may be the case that while these
compounds do not induce blatant DA toxicity individually, their co-abuse in bath salt
mixtures produces potentially damaging interactions at dopaminergic terminals.
Additionally, while the potent DAT-blocking action of MDPV has been shown to be
neuroprotective against various amphetamine toxicities (Anneken et al. 2015), in vitro
analyses suggest a synergistic interaction between mephedrone and MDPV at the DAT.
Moreover, mephedrone enhances the locomotor stimulant effects of the DAT blocker,
cocaine (Gregg et al. 2013b), and locomotor responses sensitize to drug mixtures of
MDPV and mephedrone (Berquist et al. 2016). Overall, these preclinical findings
demonstrate that the synthetic cathinones can significantly alter the DA effects of other
DAT targeting drugs when they are co-administered. Therefore, considering the
frequency of synthetic cathinone co-abuse in bath salts products, investigations into the
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combined action of these drugs on dopaminergic systems are a necessary step in
determining the pharmacology, abuse-related, and toxic effects of bath salts. The
current work has addressed the lack of experimental data regarding the combined
effects of MDPV, mephedrone, and methylone on dopaminergic tone. Moreover, the
studies described in this dissertation provide evidence of a significant pharmacological
interaction between major bath salt constituents, MDPV, mephedrone, and methylone.
The studies presented in Chapters 3 and 4 utilized a novel HPLC-ECD assay
that was optimized for fast, sensitive, and simultaneous quantitative analysis of DA and
its major metabolites in discrete DA nuclei including the substantia nigra pars compacta
(SNpc) and the ventral tegmental area (VTA) (Allen et al. 2017). This method was also
used to determine monoamine tissue content in the nucleus accumbens (NAc) and
striatum (STR). Due to very sensitive limits of quantification for all monoamines and
respective metabolites, right or left halves of discrete regions could be used for HPLC
analysis while the other half could be used for protein expression or other various
assays. Development and validation of this method in six discrete brain regions is
described in chapter 2.
The study presented in Chapter 3 of this dissertation was the first to demonstrate
a synergistic pharmacological effect of MDPV, mephedrone, and methylone on DA
levels throughout major dopaminergic brain pathways. These findings were extended to
DA-mediated behavioral responses, as illustrated by the acute onset of robust
stereotypic behavior and motor deficits with the cathinone cocktail. Such effects are
primarily reported with very high doses of potent DAT- targeting drugs and have not
been observed with any of the individual cathinones at the doses used in this study.
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These findings shed light on two major issues: 1) bath salt formulations can have
variable abuse liabilities based on their drug composition, and 2) chronic exposure to
combined synthetic cathinones may be neurotoxic, given that excessive DA elevations
have been attributed to meth-induced toxicity. The study detailed in Chapter 4 of this
dissertation addresses the latter.
Chapter 4 evaluated the neurochemical and biochemical consequences of
chronic co-exposure to MDPV, mephedrone, and methylone. Chronic dosing consisted
of repeated drug injections, given every other day for 14 days (7 total injections) and
analyses were conducted 48 h after the final exposure. In this study, chronic dosing of
the individual synthetic cathinones induced persistent increases in DA that were
accompanied by increased expression levels of the DA synthesis enzyme, tyrosine
hydroxylase (TH), and decreased levels of DA degradative enzyme catechol-Omethyltransferase (COMT). However, when MDPV, mephedrone, and methylone were
combined and chronically administered as a drug cocktail, DA, TH, DAT, MAO-B, and
COMT levels were significantly reduced. Given that many of these effects are frequently
used as neurochemical gauges of METH toxicity (Moratalla et al. 2017), we initially
hypothesized that this indicated a potentially toxic interaction between these drugs at
DA terminals. Furthermore, LDH release assays demonstrating that the individual
cytotoxic effects of MDPV, mephedrone, and methylone are exacerbated when they are
applied in conjunction with one another supported this notion. As such, further toxicity
analyses were performed in the nigrostriatal brain regions, as these are especially
susceptible to METH neurotoxicity (Ares-Santos et al. 2014). Surprisingly, we found
that chronic dosing with the cathinone cocktail did not increase striatal levels of the
138

neuroinflammatory marker, GFAP, nor did it promote a loss of DA neuronal nuclei in the
SNpc. Thus, it appears that DA, TH, and DAT levels are decreased without nerve
terminal or nuclei toxicity. From these data, we proposed combined synthetic
cathinones induce a “functional lesion,” whereby excessive increases in DA levels
immediately following each injection of the cathinone cocktail results in a
downregulation of many key players within the DA synapse after repeated dosing. This
lack of blatant neurotoxicity may be due to the weak effects of mephedrone and
methylone to increase cytosolic DA from vesicles in a VMAT2-dependent manner
(Eshleman et al. 2013; Green et al. 2014), or of full drug wash out between doses, as
METH toxicity is most notably observed following repeated, binge dosing (Halpin et al.
2014). Taken together, these data demonstrate that chronic abuse of synthetic
cathinone mixtures produces a major dysregulation of the DA system and suggest that
the toxicity of bath salts is largely dependent on the composition drugs within the
mixture.
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